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RNA editing is increasingly recognized as a molecular mechanism regulating RNA activity and 
recoding proteins. Here, I surveyed the global landscape of RNA editing in human brain tissues 
and identify three unique patterns of A-to-I RNA editing during cortical development: stable high, 
stable low and increasing. RNA secondary structure and the temporal expression of adenosine 
deaminase acting on RNA (ADAR) contribute to cis- and trans- regulatory mechanisms of these 
RNA editing patterns, respectively. Interestingly, the increasing pattern in development is most 
apparent in brain and conserved in mouse brain development. The increasing pattern associates 
with the growth of cortical layers and neuronal maturation, correlates with mRNA abundance, 
and influences miRNA binding energy. Gene ontology analyses implicate the increasing pattern 
in vesicle or organelle membrane-related genes and glutamate signaling pathways. I also show 
that the increasing pattern is selectively perturbed in spinal cord injury and glioblastoma. These 
findings reveal dynamic and functional aspects of RNA editing in brain, providing new insight 
into epigenetic regulation of sequence diversity. 
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RNA editing is a molecular process perturbing RNA sequences in a post-transcriptional manner. 
















1.1 RNA editing 
RNA editing is a post-transcriptional modification that alters RNA sequences from their 
original DNA templates. These processes affect most cellular RNAs including messenger RNA 
(mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA), as well as small RNA such as 
miRNA. RNA editing expands the repertoire of RNA transcripts, contributing to the complexity 
of genetic information through recoding amino acids and affecting regulatory roles of RNA. 
 
Overview 
In 1986, Benne et al. coined the term “RNA-editing” to describe molecular phenomena in 
which uridines were inserted or deleted in RNAs of trypanosome mitochondria (Benne et al. 
1986). Since then, the term RNA editing has been used to describe various molecular processes 
resulting in the modification of RNA sequences differing from original DNA templates (Sansam 
& Emerson 2005).  
Three types of editing (Figure 1.1) - insertion, deletion and substitution - have been 
identified in all major types of RNA (messenger, ribosomal, and transfer RNAs) as well as in 
miRNA in various species of eukaryotes, as shown in Table 1.1. In particular, eukaryotic 
organelles such as chloroplasts and mitochondria harbor the greatest variety of RNA editing 
(Gray 2012). In this study, I specifically focused on mRNA editing. 
In mammals, two substitutional types of RNA editing have been identified mainly so far: 
cytidine is converted to uridine (“C-to-U editing”) and adenosine is modified to inosine (“A-to-I 
editing”). Both are generated by a hydrolytic deamination process catalyzed by specific enzymes: 
apoB mRNA editing complex (APOBEC) for C-to-U editing and Adenosine Deaminase acting on 




The most well characterized C-to-U editing in mammals is an event found in the 
apolipoprotein B (apoB) gene, which is also the first reported instance of C-to-U editing in human 
(Powell et al. 1987). C-to-U editing in the apoB gene converts a CAA (glutamine) codon to a 
UAA (stop) codon, resulting in a truncated apoB protein due to premature termination of 
translation (Figure 1.2). Importantly, this editing event is responsible for tissue-specific 
modification of the apoB transcript. While a full-length apoB protein, denoted by apoB100 (512 
kilo daltons), is expressed in the liver, a truncated version of apoB, known as apoB48 (241 kilo 
daltons) is synthesized in intestine through C-to-U editing. Functionally, this tissue-specific 
modification of the apoB transcript has important consequences because apoB100 comprises a 
low density lipoprotein (LDL) complex that works for the transport of dietary cholesterol in liver, 
but apoB48, which lacks the C-terminal domain that in apoB100 binds to LDL receptors on cell 
membranes, is a component of the triglyceride-rich chylomicrons that deliver dietary lipids to 
intestine (Davidson & Shelness 2000). 
C-to-U editing of apoB mRNA is mediated by a multicomponent protein complex, 
APOBEC that consists of a catalytic subunit for cytidine deamination, APOBEC-1, and several 
auxiliary proteins. One cofactor is an APOBEC-1 complementation factor (ACF), which serves to 
bind a target RNA with RNA recognition motifs (Blanc & Davidson 2010). In terms of cis-
regulation, three sequence elements around the editing position, referred to as the mooring 
sequence, enhancer and spacer region, are known to be necessary factors for efficient editing 
(Backus & Smith 1992). 
Other than C-to-U editing in the apoB gene, 32 additional mRNA targets of APOBEC-1 
for C-to-U editing were identified by a recent genome-wide screen (Rosenberg et al. 2011). Here, 
4 
 
all C-to-U editing sites were found to be located in AU-rich segments of 3’ untranslated regions 
(3’ UTR) of transcripts. However, functional roles of these editing sites are not characterized yet.  
 
A-to-I editing 
A-to-I editing is the most prevalent form of RNA editing in the animal kingdom. It is 
catalyzed by a family of enzymes known as ADARs, which deaminate adenosines in double-
stranded structures of RNAs (Savva et al. 2012). The effect of A-to-I editing can be diverse 
depending on the location of the edited nucleotide, because inosine is recognized as guanosine by 
the cellular machinery. For example, A-to-I editing at protein-coding regions can change a codon 
(Pullirsch & Jantsch 2010), while it also has potential to modulate splice site usage especially 
when residing in an intron (Rueter et al. 1999; Schoft et al. 2007). 
In mammals, A-to-I editing was first identified in transcripts encoding glutamate-gated 
ion channels (Sommer et al. 1991). Here, A-to-I editing converts a glutamine (Q) to an arginine 
(R) in a gene encoding a subunit of glutamate receptors, affecting the ion permeability of the 
receptors. While originally believed to be a rare event, A-to-I editing event is now recognized as a 
widespread process in mammals. In particular, recent genome-wide studies identified huge 
number of A-to-I editing sites in human tissues (Li et al. 2011; Park et al. 2012; Ramaswami et al. 
2013). Because of its importance, A-to-I editing is discussed in detail in the next section of this 
chapter (see 1.2 A-to-I editing). 
 
Evolutionary perspectives 
RNA editing can be considered as a mechanism for adaptive evolution (Gommans et al. 
2009). It confers phenotypic variation at relatively low evolutionary cost because RNA editing is 
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not a hard-wired process - in other words, it can retain predominant production of the wild-type 
protein. If the RNA editing produces a beneficial variant, the genome may maintain the locus that 
produces the RNA-edited transcript for its novel function (Knisbacher & Levanon 2015). A 
recent example with octopus describes the utilization of RNA editing for adaptation to 
environment  (Garrett & Rosenthal 2012). While an Antartic and a tropical octopus share the 
same potassium channel gene in their genomes, they have distinct editing status at a site in the 
channel’s pore to accommodate different temperatures. Specifically, the site modulating gating 
kinetics is extensively edited, recoding an isoleucine (I) to a valine (V) in the Antarctic species 
while it is mostly unedited in the tropical species. This editing dramatically accelerates 
deactivation kinetics of potassium channels, suggestive of candidate mechanism for cold 
adaptation. This result suggests that RNA editing can contribute to the kind of adaptation to the 
physical environment achievable by genetic variation in general. Regarding this, it is 
hypothesized that RNA editing increases the evolvability of species by providing a molecular 
mechanism to express diverse phenotypic variations in response to changing environments, and 
selection may favor such a system with higher levels of genetic flexibility (Gommans et al. 2009). 
RNA editing is also involved in a process known exonization of Alu elements, where Alu 
elements can become new exons (Pandey & Mukerji 2011). Alu elements are retro-transposable 
repeat sequences in a genome, found only in primates. RNA editing can affect exonization 
through the creation of a functional 3’ splice site or “AG” and the alteration of functional exonic 
splicing enhancers within the exon (Lev-Maor et al. 2007). These observations suggest the 






1.2 A-to-I editing 
ADAR 
A-to-I editing is a deamination process of adenosines to inosine, which is mediated by the 
enzyme ADAR targeting double-stranded RNA (dsRNA). ADAR was initially characterized as a 
protein with double-stranded RNA (dsRNA)- unwinding activity (Bass & Weintraub 1987; 
Rebagliati & Melton 1987). Soon after, it was recognized as an enzyme responsible for A-to-I 
editing (Bass & Weintraub 1988; Wagnert et al. 1989). It turns out that ADAR targets duplex 
regions in RNA, switching A-U pairs to less stable I-U pairs. 
There are three ADAR genes that have so far been identified in mammals: ADAR1, 
ADAR2 and ADAR3 (Nishikura 2010). ADAR1 has two isoforms of a long “ADAR1p150” and a 
short “ADAR1p110”, which are determined by alternative promoters and different start codons. 
ADAR2 and ADAR1p110 are relatively ubiquitously expressed while ADAR1p150 is induced by 
interferon. ADAR3 is mainly detected in central nervous system but its editing capacity is known 
to be inactive, at least in-vitro. ADARs share a common structure (Figure 1.3), consisting of a 
highly conserved, C-terminal deaminase (catalytic) domain and a variable number of double-
stranded RNA-binding domains (dsRBDs) in the N-terminal half of the protein.  
The targets of ADAR1 and ADAR2 differ but also overlap (I. X. Wang et al. 2013). For 
example, in GluA2, a key subunit of the AMPA receptor, the editing site converting an amino 
acid from glutamate (Q) to arginine (R), called as ‘Q/R site’, is only edited by ADAR2, while the 
site changing arginine (R) to glycine (G), denoted as ‘R/G site’, can be edited by both ADAR1 
and ADAR2 (Higuchi et al. 2000).  
ADARs are essential in mammals although ADAR-null inverterbrates are viable with 
behavioral defects. Specifically, ADAR1-knockout mice are embryonic lethal at embryonic day 
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12.5 (E12.5) owing to defects in erythropoiesis, stress-induced apoptosis, liver disintegration, and 
overproduction of type I interferon (Wang et al. 2004; Hartner et al. 2004). Mice that lack ADAR2 
died within 3 weeks after birth as a result of seizures (Brusa et al. 1985; Higuchi et al. 2000). In 
the case of C. elegans with homozygous deletions of both ADAR1 and ADAR2, defective 
chemotaxis is observed (Tonkin et al. 2002). Drosophila without the ADAR locus exhibits 
uncoordinated locomotion and age-dependent neurodegeneration (Palladino et al. 2000). 
Interestingly, the impaired phenotype caused by knockout of ADAR2 in mice can be rescued by 
introducing an arginine (R) codon at the Q/R site in GRIA2 (Higuchi et al. 2000), implying that 
Q/R editing is essential for survival in ADAR2-mediated A-to-I editing. However, the rescued 
ADAR2 knockout mouse still showed significant changes in behavior, hearing ability, allergy 
parameters and transcript profiles of brain, suggesting that ADAR2 affects broad physiology in 
mice (Horsch et al. 2011).  
 
Site-selective editing and hyper-editing  
ADARs can deaminate various numbers of adenosines in a target mRNA. Because of this 
characteristic, A-to-I editing can have two different modes: site-selective and nonselective, called 
hyper-editing. Typically, in site-selective editing, one or a few A-to-I editing sites are observed. 
In the case of hyper-editing, multiple adenosines are subjected to deamination (Wahlstedt & 
Ö hman 2011). Coding regions of mRNAs usually undergo site-selective deamination while 
noncoding regions of mRNA such as introns and untranslated regions (UTRs) tend to be a target 
of hyper-editing.  
Previous studies demonstrate that the number of A-to-I editing sites usually increases 
with the length of RNA duplexes and is affected by structure of RNA duplexes. Site-selective 
editing is often found in short duplexes, between 15 and 40 bp in length, interrupted by bulges 
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and internal loops. Hyper-editing, on the other hand, is usually observed in long (greater than 50 
bp) and almost completely base-paired dsRNA (Hundley & Bass 2010). 
Hyper-editing is enriched in Alu elements because their genomic structure is favorable to 
form a long and perfect double-stranded structure when expressed. The Alu repeat element with 
about  300 nucleotides in length is the most abundant primate-specific retroelement, and makes 
up more than 10% of the human genome. Most Alu repeats are located within genes (usually in 
introns or 3’ UTRs), and are hence transcribed as part of the pre-mRNA transcript of the gene. 
Owing to the abundance of Alus, it is very frequent to find mRNA transcripts containing two 
nearby Alus in opposite orientation. As the mRNA molecule folds, these two Alus may form 
secondary RNA structures that are targeted by ADAR, resulting in a substrate for hyper-editing 
(Knisbacher & Levanon 2015). Recent genome-wide studies of the human transcriptome (Blow et 
al. 2004; Sakurai et al. 2014) confirm large numbers of A-to-I editing associated with Alu 
elements. 
 
Molecular function of A-to-I editing 
Site-selective editing in coding sequence (CDS) can alter amino acid sequences, 
diversifying protein isoforms. A limited number of cases have been identified so far, especially in 
genes involved in the central nervous system, such as ligand- and voltage-gated ion channels as 
well as G-protein-coupled receptors. In most cases, A-to-I editing creates multiple isoforms of 
proteins essential for balanced neuronal kinetics (Rosenthal & Seeburg 2012). Several examples 
are reviewed in a detail in the next section (1.3 A-to-I editing in brain and disease). 
Site-selective editing is also found in intronic regions and has the potential to modulate 
splice site usage (Rueter et al. 1999; Schoft et al. 2007). The exemplary case is an A-to-I editing 
found in ADAR2 (Figure 1.4). Here, A-to-I editing in an intron between exon3/4 and exon 5 of 
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ADAR2 generates 3’ splicing signal (‘AG’), producing a longer transcript containing the 47-
nucleotides insert. Insertion of the 47-nucleotides induces decreased ADAR2 protein expression, 
representing a negative autoregulatory mechanism by which ADAR2 can prevent its own 
expression (Rueter et al. 1999). 
Moreover, site-specific editing in 3’ UTRs evades or creates the binding of miRNA 
(Liang & Landweber 2007; Q. Wang et al. 2013). Specifically, Wang et al. showed that A-to-I 
editing in ARHGAP26, a negative regulator of the Rho family essential for muscle development, 
disrupts the binding of miR-30b-ep and miR-573, resulting in the loss of repression by these 
miRNAs (Q. Wang et al. 2013).  
Functional roles of hyper-editing are not well characterized yet but several studies have 
suggested their functions. First, previous studies showed that synthetic inosine-containing RNAs 
are specifically retained in the nucleus, which is mediated by RNA-binding protein, p54nrb 
(Zhang & Carmichael 2001; DeCerbo & Carmichael 2005). They proposed the possibility that 
nuclear retention of inosine-containing RNA works as a cellular mechanism to suppress gene 
expression. In fact, an endogenous inosine-containing RNA in mouse, Cat2 transcribed nuclear-
RNA (Ctn RNA) was shown to be retained in the nucleus and released upon cleavage (Prasanth et 
al. 2005). It should be noted here that a nuclear structure, the paraspeckle was involved in this 
nuclear retention, and p54nrb was found in the paraspeckle. 
Second, hyper-edited RNA is known to be a target of tudor staphylococcal nuclease 
(Tudor-SN), an eukaryotic RISC (RNA-induced silencing complex) subunit. A previous in-vitro 
study showed that Tudor-SN specifically interacts with and promotes cleavage of synthesized 
hyper-edited dsRNA substrates containing I-U and U-I pairs  (Scadden 2005). However, no 
endogenous substrate of Tudor-SN has been reported so far. Some researchers hypothesized that  
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endogenous RNA is targeted by Tudor-SN only in response to certain environmental conditions 
(Hundley & Bass 2010). 
Lastly, there were reports that hyperedited dsRNA can exert its functions in trans. For 
example, inosine-containing dsRNA lead to global downregulation of gene expression (Scadden 
2007), which is mediated by stress granules (SGs) interacting with edited transcripts. Also, the 
same group showed that hyperedited dsRNA with multiple IU pairs suppresses interferon 
induction and apoptosis (Vitali & Scadden 2010).  
All of these studies demonstrated direct or indirect roles of hyper-editing, especially for 
sites in 3’ UTR. However, their functional roles are still under debate. For example, endogenous 
mRNA with multiple inosines in their 3’ UTRs have been found in mammalian and C. elegans 
cell cytoplasm, arguing that nuclear retention of inosine-containing RNA is not a general 
phenomenon  (Hundley & Bass 2010). The roles of hyper-editing might be diverse depending on 




1.3 A-to-I editing in brain and diseases 
A-to-I editing in brain 
It is believed that A-to-I editing is most abundant in brain among all mammalian tissues 
(Table 1.2) (Paul & Bass 1998). In fact, some important A-to-I editing events are found in the 
nervous system. These A-to-I editing events are often involved in amino acid changes regulating 
neurotransmission. The followings are some important examples of A-to-I editing. 
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The first example is A-to-I editing in glutamate receptors. In fact, this is the first A-to-I 
editing found in mammals (Sommer et al. 1991). It was found serendipitously while researchers 
studied the excitatory glutamate receptors. Cloning of the mammalian AMPA receptor subunit 
GRIA2/GluA2 showed a discrepancy between the mRNA and the corresponding DNA template, 
which indicated A-to-I editing. The function of the editing is significant because it recodes amino 
acids from a glutamine (Q) to an arginine (R) around the channel pore, affecting the permeability 
of calcium ions. In normal physiological situations, full editing prevents calcium ions from 
moving through the assembled receptors. The failure of this editing causes epileptic seizures and 
death in mice (Higuchi et al. 2000). In addition to AMPA glutamate receptors, kainate glutamate 
receptors including GRIK1/GluR5 and GRIK2/GluR6 also have Q/R editing (Barbon & Barlati 
2011). In particular, GRIK2 Q/R editing is involved in synaptic plasticity via long-term 
potentiation (Vissel et al. 2001). In glutamate receptors, there is another important A-to-I editing 
site, namely an R/G editing site where an arginine (R) is converted to glycine (G) in the 
extracellular ligand binding domain of the receptors (Barbon & Barlati 2011). This is mainly 
found in subunits of AMPA receptors such as GRIA2/GluA2, GRIA3/GluA3 and GRIA4/GluA4. 
Editing at this site increases the recovery rate from desensitization of the ion channels, allowing 
faster response to repeated impulses (Kappler et al. 2002). 
The second A-to-I editing example involves the serotonin receptor. Serotonin or 5-HT is 
a neurotransmitter that modulates a wide array of physiological processes including mood, 
appetite, pain perception, locomotion, memory and sexual behavior (Roth 2006; Berger et al. 
2009). RNA editing is found in one of the G-protein-coupled serotonin receptor, 5-HT2cR. The 
A-to-I editing in 5-HT2cR, which alters the amino acid sequences of the second intracellular loop 
of the receptor, lead to a 10~15 fold reduction in the efficacy of the interaction between receptors 
and their G proteins  (Burns et al. 1997). Because 5-HT2cR is involved in many human 
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psychiatric and behavioral disorders including depression and schizophrenia, the A-to-I editing in 
5-HT2cR draws much attention in terms of clinical implications (O’Neil & Emeson 2012). 
The last example is A-to-I editing found in a voltage –gated potassium channel, Kv1.1. 
The Kv1.1 is one of the most widely expressed voltage-gated potassium channel playing an 
important role in excitability by repolarizing membranes and shaping the firing properties (Jan & 
Jan 2012). A-to-I editing in the Kv1.1transcript substitutes an isoleucine (I) for a valine (V) in the 
highly conserved ion-conducting pore of the channel, resulting in an increased recovery rate of 
the channel (Bhalla et al. 2004). This is an example showing that A-to-I editing shapes the action 
potential, a fundamental element of the neuronal system.  
 
A-to-I RNA editing in brain development 
Interestingly, some A-to-I editing events are differentially regulated in brain development 
and these differential regulations of A-to-I editing are expected to have functional significance in 
this respect. For example, several sites including the R/G site in glutamate receptors (e.g. GRIA2, 
GRI3, GRIA4) show a gradual increase in editing during brain development (Wahlstedt et al. 
2009). Considering the effects of R/G editing on functions of glutamate receptors, it can be 
hypothesized that unedited status of R/G editing sites of glutamate receptors in fetal brain makes 
the recovery of the receptors from desensitization slow, which avoids their hyper-activation under 
elevated glutamate conditions. 
Another instance can be found in GABAA receptors, a ligand-gated chloride channel. The 
GABAA receptor produces a hyperpolarizing influx of chloride ions when active in the mature 
brain. However, it generates depolarizing currents creating an excitatory response to GABA in 
fetal brain, which is crucial for a number of developmental processes including proliferation and 
synaptogenesis (Ben-Ari 2014). This functional switching is largely due to different subunit 
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composition of the receptors. The alpha subunit is particularly important as alpha3 (GABRA3) is 
found in the receptor in fetal brain while alpha1 (GABRA1) is expressed in adult brain (Rula et al. 
2008). A-to-I editing in GABRA3 in part plays a role here because an edited GABRA3 transcript 
tends to be inefficiently transported to neurites and falls under enhanced lysosomal degradation, 
contributing to a component change of GABAA receptors from GABRA3 to GABRA1 (Daniel et 
al. 2011). 
A recent study discovered a more striking case regarding A-to-I editing change in 
neuronal differentiation (Pachernegg et al. 2015). In general, GRIA2 Q/R site is known to be 
almost exclusively edited across brain development. However, Pachernegg et al. showed that 
editing levels of GRIA2 Q/R site increases rapidly during the very early stages of in vitro neural 
differentiation. They also demonstrated that neural progenitor cells (NPCs) express glutamate 
receptors permeable to calcium ion, when GRIA2 remains unedited by Q/R editing. Consistent 
with these results, delivery of ADAR2 into NPCs prevents neuronal differentiation (Whitney et al. 
2008). Along with a gradual increase of R/G editing in brain development, a rapid increase of 
Q/R editing during early neurogenesis highlights the importance of A-to-I editing in neuronal 
development. 
 
A-to-I RNA editing in diseases 
Dysregulation of A-to-I editing is observed in many diseases, primarily neurological or 
psychiatric diseases (Gallo & Locatelli 2012). For example, aberrant A-to-I editing in GRIA2 is 
implicated in amyotrophic lateral sclerosis (ALS), malignant glioma and ischemia (Yamaguchi et 
al. 1999; Maas et al. 2001; Kawahara & Kwak 2004). Also, imbalance of A-to-I editing in the 
serotonin receptor, 5-HT2cR was found in psychiatric diseases such as suicide and schizophrenia 
(Niswender et al. 2001; Sodhi et al. 2001). However, psychiatric associations of A-to-I editing in 
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general are still debates (Lyddon et al. 2012; Eran et al. 2013). Moreover, functional roles of A-
to-I editing in pathological conditions are largely unclear although deficiency of A-to-I editing at 
GRIA2 Q/R site is related to death of neuronal cells in some pathological conditions such as 






























Figure 1.2 RNA editing in apolipoprotein B (apoB) mRNA. C-to-U editing at cytidine 6666 in 
apoB mRNA generates a protein isoform functionally different from the unedited one. LDL: low-
































Figure 1.4 A-to-I editing in ADAR2. A-to-I editing in an intron between exon 3/4 and exon 5 
















Type of editing edited RNAs Organisms Genetic system 































cox1 mRNA P. polycephalum mitochondrial 
cox1, cox3 
mRNAs 
Naegleria gruberi mitochondrial 
U-to-C substitution 












metazoan animals nuclear 
 
Table 1.1 Examples of RNA editing in Eukaryotes. N insertion means insertion of C, U, 
dinucleotide. ‘nuclear/mitochondrial’ indicates that the substrate is a nucleus-encoded tRNA that 







Tissue IMP (pmol) One IMP for every: 
Brain 1.8 ± 0.9 17,000 nt 
Lung 0.9 ± 0.7 33,000 nt 
Heart 0.9 ± 0.6 33,000 nt 
Thymus 0.5 ± 0.3 60,000 nt 
Muscle 0.2 ± 0.1 150,000 nt 
 
Table 1.2 Amounts of IMP in different rat tissues. IMP: inosine monophosphate. This table is 

















Identification of RNA editing events from genome-wide sequencing of 
RNA (RNA-seq) 
 
In order to accurately identify RNA editing sites using RNA-seq, a computational pipeline is 
necessary to reliably identify RNA editing sites. In this chapter, I will review issues in identifying 
RNA editing sites from RNA-seq and describe the computational tool developed in this study to 













In principle, detecting RNA editing events is straight forward because it just requires 
comparisons of RNA sequences or complementary DNA (cDNA) sequences with template DNA 
sequences. In particular, A-to-I editing is easily identified as an adenosine to guanosine (A-to-G) 
discrepancy in the comparison because an inosine base pairs with cytosine in cDNA synthesis and 
Sanger sequencing. In fact, several important A-to-I editing sites were found serendipitously 
through comparisons of cDNA with the genomic sequence.  
With the recent advent of next generation sequencing (NGS) technology that generates a 
huge number of short sequences (“sequencing reads”) in a parallel way, it is now possible to have 
sequence information from DNA or RNA at a genome-wide level, where the genome-wide 
sequencing of DNA and RNA are referred to as “whole-genome sequencing” and “RNA-seq”, 
respectively. Now, RNA editing can be found in a systematic way at a genome-wide level by 
comparing sequences between whole-genome sequencing and RNA-seq obtained from the same 
sample. 
However, because whole-genome sequencing is still inefficient in terms of cost, an 
efficient way to identify RNA editing using only RNA-seq has been of special interest in the 
RNA editing field. In particular, it is still daunting to perform both whole-genome sequencing and 
RNA-seq for all the samples in a study necessary for a large sample size. A typical approach to 
identify RNA editing from the only RNA-seq is to compare sequencing data from RNA-seq with 
a reference genome, and controlling for false-positive calls at a reasonable rate. In this chapter, I 
will review several issues in the discovery of RNA-editing from RNA-seq and present the 




2.2. Issues in identifying RNA editing sites from RNA-seq data only 
There are three main issues in calling RNA editing sites from RNA-seq: contamination of 
genomic variants, technical errors originating from inherent RNA-seq technology, and errors 
introduced by an alignment step during processing of RNA-seq data. 
  
Contamination of genomic variants 
When RNA editing is called from RNA-seq without the corresponding DNA template 
information, a typical approach is to compare RNA sequence determined by RNA-seq with a 
reference genome and detect sequence discrepancies as putative RNA editing sites. But 
significant proportions of these candidates are likely genomic variation, especially due to single 
nucleotide polymorphisms (SNPs) (Figure 2.1). Therefore, the false positive rate in the initial call 
obtained from a simple comparison between RNA-seq with reference genome is unacceptably 
high.  
 
Technical errors inherent to sequencing technology 
A typical sequencing read from NGS has non-uniform sequencing qualities from base to 
base. Generally, 3’ ends of sequencing reads have poor sequencing quality (Figure 2.2). 
Therefore, one should be cautious if a called RNA editing site is enriched by sequencing reads 
whose bases at the editing site have poor sequencing qualities. For a given base of a sequencing 
read, sequencing quality is quantified by the Phred score, Q defined as follows: 
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where P is the probability that the base is called wrong. A Phred score smaller than 20 indicates 
that the accuracy of the base call is less than 99%. In addition to non-uniform sequencing 
qualities, 5’ ends of sequencing reads can have random sequence regardless of biological sources 
due to a PCR step with random primers necessary for the preparation of a sequencing library.  
 
Alignment errors in RNA-seq 
Although most of sequencing reads from RNA-seq are accurately aligned to the reference 
genome when aligned by commonly-used software such as TopHat (Trapnell et al. 2009) or 
STAR (Dobin et al. 2013), there are still sequencing reads that are aligned ambiguously, mainly 
around the regions with RNA splicing and repeat sequence. Although these ambiguously-mapped 
reads may not be a critical problem when using RNA-seq as a tool to estimate mRNA abundances, 
currently a main reason for performing RNA-seq, they should be critically considered for an 
RNA editing study as they can be a source of false positive calls of RNA editing sites (Kleinman 
& Majewski 2012). 
 
 
2.3. Development of computational tools to identify RNA-editing from 
RNA-seq data 
In order to accurately identify RNA editing sites using RNA-seq, I developed a 
computational pipeline to make reliable calls of RNA editing sites, considering the issues 
discussed in the previous section. This pipeline consists of several steps including alignment, 




RNA-seq reads were aligned by BWA (Li & Durbin 2009) to the reference genome 
(UCSC hg19) as well as the annotated transcriptome obtained from several public databases 
including NCBI RNA reference sequence collection (RefSeq), UCSC and Ensembl. Using the 
combined transcript information from multiple databases and not attempting to detect novel 
isoforms from RNA-seq data help to avoid false positives due to alignment errors. 
 
Variant calling 
After alignment is done, putative RNA editing sites were identified by a variant-calling 
software, “Genome Analysis Toolkit” (GATK) (DePristo et al. 2011), using uniquely mapped 
reads after PCR duplicates were removed by the Picard tool (Auwera et al. 2013). Note that A-to-
I editing events appear as A-to-G discrepancies in variant-calling.  
 
Computational Filters 
For initial list of RNA editing sites, computational filters were applied to deal with the 
major issues in calling RNA editing sites from RNA-seq: (1) contamination of genomic variants, 
and (2) false positives due to sequencing or alignment errors. In our pipeline, potential genomic 
variants were filtered out through three steps: (i) removing all known SNPs in dbSNP version 137 
(Sherry et al. 2001) except for SNPs of molecular type “cDNA”; (ii) taking out sites with variant-
supporting reads only under the assumption that 100% editing efficiency is unrealistic; (iii) 
keeping variants detected in at least two individuals because they are unlikely to be rare variants. 
Possible false positive RNA editing sites due to sequencing or alignment errors were removed by 
taking advantage of their tendency to have bias in terms of positions on a sequencing read and 
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strands (Kleinman & Majewski 2012). After categorizing sequencing reads spanning a putative 
RNA editing site into two groups, a reference-supporting group and a variant-supporting group 
according to the alleles in the reads, we applied a two sample t-test and a Fisher-exact test to see 
if the two groups were statistically different in terms of position bias (Figure 2.4) and strand bias 
(Figure 2.5), respectively. For a given site, the position on a sequencing read was defined as the 
smaller distance from either end of the read. If the p-value from the test was smaller than a given 
threshold, the site was declared as a false positive. In this study, 0.01 was chosen as the p-value 
threshold and used Bonferroni-correction for multiple testing correction.  
 
Final call of RNA editing sites 
Finally, reliable RNA editing sites were identified if there were enough sequencing reads 
at the sites, such that at least one individual had more than or equal to 5 high-quality (PHRED 
score ≥ 20) reads and more than two high-quality and variant-supporting reads were found in at 
least one person. Sites with two or more variants were excluded under the assumption that RNA 
editing is generated only by transition from purine to purine or pyrimidine to pyrimidine. 
 
 
2.4. Validation of the computational tool 
In order to evaluate the developed computational pipeline, we obtained both DNA and 
RNA sequence information from two samples. Specifically, two pairs of DNA exome-sequencing 
(exome-seq) and RNA-seq were generated and used to estimate the false discovery rate (FDR) of 
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the developed pipeline, under the assumption that observed DNA and RNA sequence differences 
are mainly caused by RNA editing.  
 
Exome-sequencing 
Exome-sequencing is a variant of whole genome sequencing. Here, instead of sequencing 
a genome, exon regions are enriched and sequenced. For a given sequencing capacity, exome-
sequencing gives much higher number of sequencing reads for exonic regions, compared to 
whole genome sequencing, which makes it possible to call accurate genotype. I used the Agilent 
Sure Select Capture system to enrich exonic regions from DNA samples.  
 
Validation 
First, RNA editing sites were identified from individual RNA-seq through the above 
pipeline, except for the step requiring the multiple samples. Second, genotypes for RNA editing 
sites were called from matched exome-seq using uniquely-mapped reads as determined by BWA 
and GATK pruning tools for realignment and recalibration (Auwera et al. 2013). A given 
genomic site was declared as homozygous if reads supporting major alleles comprise a proportion 
greater than 90% of the sequencing depth. Finally, the false discovery rate (FDR) was estimated 
with the sites whose sequencing depths in exome-seq were greater than or equal to 20 to ensure 
reliable genotype calls. Here, false positives are RNA editing sites where corresponding genomic 
sites do not have homozygous genotypes with the reference allele. FDR of two matched sets are 
5.1% and 6.0%, respectively (Table 2.1). It should be noted that the additional filters in the 
pipeline, which take advantage of the multitude of samples, were not used for this evaluation but 





Figure 2.1 False positive call of RNA editing at SNP sites. Two sites are shown where RNA 
editing sites are initially called from RNA-seq (top) as reference sequences are T and C but 
sequencing reads have C and A at the sites, respectively. However, they are previously-annotated 
SNP sites (rs3748956 and rs819976). In fact, they turned out to be false positives, based on DNA 






Figure 2.2 Varying sequencing qualities in a sequencing read. Histogram shows the 
distribution of Phred score across sequencing reads in a single run according to the position in a 
read. Here, the size of a sequencing read is 36 base. The average sequence quality, denoted by the 








Figure 2.3 Computational pipeline to identify RNA editing sites from RNA-seq. Step-by-step 







Figure 2.4 Position bias filter. For a given site, reference-supporting reads and variant-
supporting reads are identified. They are statistically compared in terms of distance from an end 
of the sequencing reads. In the figure, aligned sequencing reads denoted by gray horizontal bars 
are described. Vertical dotted line indicates a site to be tested, where the reference is G (with no 
letter indication) and the variant is T (marked by red letter). Blue circle and red circle describe 
two groups consisting of reference-supporting reads and variant supporting reads, respectively. 





Figure 2.5 Strand bias filter. For a given site, reference-supporting reads and variant-supporting 
reads are identified. They are statistically compared in terms of strand of sequencing reads. In the 
figure, aligned sequencing reads denoted by gray horizontal bars are described. Vertical dotted 
line indicates a site to be tested, where the reference is A (with no letter indication) and the 
variant is T (marked by red letter). Two by two tables are constructed, as shown in the figure, to 
































B925 D2136 R3763 83,059,552 55,271 4,833 250 5.1 
B1016 D2278 R3670 112,386,874 214,400 7,119 428 6.0 
 
Table 2.1 Evaluation of computational pipeline for identifying RNA editing from RNA-seq. 
Two matched sets of DNA exome-sequencing (exome-seq) and RNA-seq were generated to 
evaluate the performance of our computational pipeline to identify RNA editing sites from RNA-
seq. RNA editing sites were identified from RNA-seq through the pipeline described in methods, 
except for the step requiring the multiple samples. The false discovery rate (FDR) was estimated 
with the sites whose sequencing depths in exome-seq were greater than or equal to 20 (testable 














Landscape of RNA editing in human brain development 
 
Here, I analyzed RNA-seq in post-mortem human brain tissues obtained from a total of 33 
individuals spanning fetal to old age in order to generate comprehensive RNA editing profiles in 
human cortical development. In addition to confirming previous results about RNA editing, I 
found that the genome-wide landscape of A-to-I editing reflects a set of uniquely regulated RNA 













3.1. Significance of RNA editing study in human brain development 
Despite the apparent frequency and consequence of RNA editing in brain as discussed in 
the Chapter 1, its broader regulation and functional roles are unclear (Li & Church 2013). In 
particular, the contribution of RNA editing is largely unexplored in human cortical development 
where diverse molecular processes must be orchestrated in a timely and precise manner. Previous 
studies investigating  A-to-I editing in human brain have offered a very limited picture of editing 
sites and of their developmental variation (Blow et al. 2004; Li & Church 2009; Li et al. 2013; 
Ramaswami et al. 2013; Sakurai et al. 2014). For examples, prior studies have looked at only 
known editing sites (Li et al. 2013) or only in adult brain samples (Blow et al. 2004; Sakurai et al. 
2014). This limited profile of RNA editing makes it impossible to elucidate mechanisms or 
functions in the development of the nervous system. A single previous study that explored global 
A-to-I editing profiles across brain development in the mouse (Dillman et al. 2013) did not 
address mechanistic or functional implications. More importantly, the results from mouse brain 
tissues are limited in their translation into RNA editing in human brain, particularly as A-to-I 
editing is enriched in Alu repeats, a primate-specific DNA element (Athanasiadis et al. 2004; Kim 
et al. 2004). Therefore, it is valuable to investigate comprehensive RNA editing profiles in human 
cortical development, which can provides insights to understand the function and regulation of A-
to-I editing.   
 
 
3.2. Post-mortem human brain samples 
Post-mortem brain tissues from 33 individuals without neurological or psychiatric  
illnesses were obtained as previously described (Jaffe et al. 2015) and dissected at the Lieber 
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Institute for Brain Development (LIBD), USA. Specifically, the samples are of prefrontal cortex 
(DLPFC) grey matter (BA 9/46) spanning from birth to the eight decade of life. Fetal tissue was 
taken from the prefrontal region, over the dorsal convexity of the frontal lobe just anterior to the 
temporal pole. The samples were categorized into six distinct life stages: fetal, infant (< 12 
months), child (1≤ age <10), teen (10≤ age <20), middle (20≤ age <50) and old life (age ≥ 50). In 
addition, 20 brain samples were collected from 5 additional healthy old individuals, each 
generating four samples for different brain regions including dorsolateral prefrontal cortex 
(DLPFC), cerebellum (CB), hippocampus (HIPPO), and entorhinal cortex (ERC). In order to 
reduce heterogeneity in the samples, only brain tissue from Caucasian individuals were collected. 
The demographic details of the samples are presented in the Table 3.1. 
 
 
3.3. Identification of RNA editing sites from RNA-seq across human 
brain development 
RNA-seq 
The poly-A enriched RNA-seq libraries were prepared according to the standard Illumina 
protocol. RNA-seq was performed to generate paired-end reads with 100-bp read length. 
Approximately 120M reads per sample were acquired (Tables 3.2).  
 
Identification of RNA editing sites 
As a discovery set to identify RNA editing sites, 33 DLPFC samples were interrogated by 
the computational pipeline described in Chapter 2. This results in the genome-wide identification 
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of RNA editing sites across human brain development. RNA editing types were assigned based 
on strand information from RefSeq. 
 
 
3.4. Landscape of RNA-editing in human brain development 
Global characteristics of RNA editing in human brain development 
A total of 267,766 RNA variant sites were identified in our 33 fully sequenced samples 
across brain development. On average, over 66,000 sites were identified in an individual sample 
(Table 3.2). Four major variant types were identified in genic regions, including A-to-G, T-to-C, 
G-to-A and C-to-T, each comprising a proportion greater than 1% (Fig. 3.1 and Table 3.3). While 
T-to-C and G-to-A variants are not canonical RNA editing types, they can be understood as 
possible A-to-I editing and C-to-U editing, respectively, if we consider incomplete strand 
annotation or antisense transcription. With this consideration, the proportion of the two known 
RNA editing types (A-to-I and C-to-U) accounts for most of the RNA variants in the list (94%). 
In particular, A-to-I editing sites are disproportionately enriched, as expected. I also confirmed 
that 85.5% of the identified A-to-I editing sites have been found in previous studies of various 
human tissues (Ramaswami & Li 2014) (115,336 of 134,914 sites). These results collectively 
indicate a successful identification of RNA editing sites in our study.  
Next, A-to-I editing was focused, which is the most enriched editing type in human brain 
development. It is found mainly in introns and in 3’ UTRs as well as in Alu repeat regions (Table 
3.4), which is consistent with previous studies using human brain tissues (Blow et al. 2004; 
Sakurai et al. 2014). Interestingly, as shown in figure 3.2, a large proportion of RNA editing sites 
in coding sequence (CDS) regions and 5’ UTRs are not within Alu repeat regions that frequently 
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form double-stranded RNA secondary structures required for ADAR’s target recognition. This 
indicates that A-to-I editing in CDS regions and in 5’ UTRs is not simply a reflection of 
expansion of Alu repeats in primate evolution. 
 
Landscape of A-to-I editing rates in human brain development 
To explore A-to-I editing quantitatively on a genome-wide scale, the A-to-I editing rates 
were estimated across all samples. For a given RNA editing site in a given sample, the A-to-I 
editing rate was estimated as a ratio of the number of reads supporting RNA editing to the total 
number of reads covering that site (Figure 3.3). Only aligned reads with high sequencing quality 
(PHRED score ≥ 20) on the sites were used. A-to-I editing rates was compared across the six age 
groups: namely, fetal, infant, child, teen, middle and old age. Specifically, in order to identify 
differentially edited A-to-I editing sites across developmental stages, the sites on mRNA structure 
(5’UTR, CDS and 3’ UTR) whose median number of reads across samples was greater or equal 
to 20 were evaluated by ANOVA among the six age groups followed by multiple test correction 
with FDR. 0.01 was chosen as a significance cutoff of FDR adjusted p-values. 748 sites were 
identified as ones with significant editing rate differences among the six age groups. Among these 
sites, 742 sites have a developmentally-increasing editing pattern from fetal to adult samples 
(Figure 3.4a, top in Figure 3.4b and Table 3.5). These increasing sites were found in at least 10 
samples (Figure 3.5) and comprise five clusters based principally on their relative baseline editing 
rates during fetal life (Figure 3.6). In contrast, most of the other editing sites show stable editing 
rates across samples from fetal age to late life. Specifically, the majority of these stable sites 
showing low editing rates have a mean rate of about 0.1, but there are a few sites with stably high 
editing rates around 0.9 (bottom in Figure 3.4b). These global editing rate profiles during brain 
development were highlighted with three unique labels: ‘stable high editing’, ‘stable low editing’ 
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and ‘increasing editing’, which are hereafter collectively called ‘developmental A-to-I editing 
patterns’ (Figure 3.4b).  
 
3.5. Comments on the increasing pattern 
Because the increasing editing profile might also reflect cell composition change towards 
relatively more glia postnatally, I considered the possibility that increasing populations of glia 
account for these regional and developmental differences. However, in an available dataset with 
purified mouse cortical cells (Zhang et al. 2014), CDS-residing editing sites in the increasing 
pattern generally have higher editing rates in neurons than in non-neuronal cell types (Table 3.6). 
Also, in a comparison of mRNA levels of ADARs among different cell types using a previous 
human brain single-cell RNA-seq dataset (Darmanis et al. 2015), neurons have higher ADAR 
expression levels than various glial cell types (Figure 3.7). Thus, the possibility that the 
increasing pattern is related to relative glial enrichment in postnatal brain samples is highly 
unlikely. This is further confirmed by an analysis of editing rates after normalization to neuronal 
and/or glial proportions. After estimating relative neuronal and glial composition using a 
previously-proposed computational method (Jaffe et al. 2015) with available genome-wide DNA 
methylation data (Jaffe et al. 2016) from the same postnatal brain tissues in the 33 discovery set, 
we find that the increasing pattern in brain development is found to be present after the 
normalization of editing rates (Figure 3.8). Here, for fetal samples, two independent fetal tissues 
were used, which have both DNA methylation and RNA-seq datasets (Table 3.7). Finally, it 
should be noted that cerebellum, which has the highest proportion of neuronal cells among brain 
tissues, has both higher and lower editing rates, compared to neocortical regions, at the sites 
showing the increasing editing pattern in brain development (Figure 3.9 with Table 3.8). Because 
neurons have higher ADAR expression levels compared to other cell types as described, the 
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simple proportional differences of neuronal or glial population do not explain the lower editing 
rates at some sites in cerebellum. In this analysis, 20 brain samples (Table 3.7) were collected 
from 5 additional healthy old individuals, each generating four samples for different brain regions 
including dorsolateral prefrontal cortex (DLPFC), cerebellum (CB), hippocampus (HIPPO), 
entorhinal cortex (ERC). When editing rates were compared among brain regions, repeated 
measures ANOVA followed by FDR was performed to identify the editing sites showing 
differences across brain regions. These results collectively suggest that spatiotemporal changes of 












Figure 3.1 RNA editing types in human brain development. A-to-I editing is 
disproportionately enriched among RNA variants. A-to-I editing is described as A-to-G variant. 













Figure 3.2 Distribution of A-to-I editing sites according to gene regions. The numbers of A-
to-I editing sites across genic regions are shown at the top of the grey bar. The proportion of 













Figure 3.3 Examples of RNA editing rates. For a given site whose reference is ‘T’, editing rates 
are different between two samples: in R3497, 37 sequencing reads support the allele ‘C’ among a 
total of 41 reads, assigning 0.9 (≈37/41) as an editing rate. In R5807, only 5 reads in 38 reads 










Figure 3.4 Genome-wide profiles of A-to-I editing rates in human brain development. (a) 
The editing rates for 4,282 A-to-I editing sites that have higher median numbers of sequencing 
reads in 33 brain samples. For a given RNA editing site in a given sample, the A-to-I editing rate 
was estimated as a ratio of the number of reads supporting RNA editing to the total number of 
reads covering that site. Color (from blue to red) indicates editing rate (from 0 to 1) for a given 
site (row) in a sample (column). Samples are ordered according to age from fetal (left) to old age 
(right). The differentially edited sites (marked as significant) across the six age groups are 
determined by ANOVA with multiple testing correction. The significantly increasing sites are 
clustered into five groups denoted by numbers in the figure, which vary principally by their 
absolute editing rates and not by the slope of developmental change (see figure 3.6). (b) The top 
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figure is the histogram of mean editing rate differences between prenatal age group and post-
infant age groups for significant sites while the bottom histogram describes the mean editing rate 
across 33 samples for non-significant sites. Overall, the global profiles of A-to-I editing rates in 
human brain development are summarized by three patterns: ‘stable low editing’, ‘stable high 















Figure 3.5 The number of sites with increasing pattern in 33 human brain samples. (a) 
Histogram of the number of editing sites according to the number of samples at which editing 
sites occur: Testable sites are sites whose median sequencing depth across samples is greater than 
20 in mRNA regions (5’ UTR, CDS and 3’ UTR), which correspond to all sites in figure 3.4. The 
increasingly-edited sites indicate the sites with the increasing pattern in figure 3.4. (b) The 
cumulative proportion of the increasingly-edited sites according to the number of samples at 
which editing sites occur: only 14% of sites were found in 10 samples or less. In other words, 





Figure 3.6 Increasing editing patterns. The significant sites determined by ANOVA followed 
by FDR-correction have an increasing editing pattern which is represented by five groups varying 
in their absolute editing rates but not in their slopes (noted by numbers) based on hierarchical 
clustering. Lines are generated by fitting generalized additive models (GAM) to data with 









Figure 3.7 Comparison of ADAR RNA level across cell types. (A) ADAR1 (B) ADAR2. 
Normalized counts of sequencing reads from a previous single cell RNA-seq dataset (Darmanis et 
al. 2015) were used to compare RNA levels across cell types. Each dot represents a single cell. 













Figure 3.8. Increasing pattern normalized by neuronal or glial proportions in human brain 
development. (a) The proportions of four cell types including embryonic stem cells (ES), neural 
progenitor cells (NPC), neuronal cells (NeuN pos) and glial cells (NeuN Neg) were estimated 
from the same brain tissues in the 33 subject discovery set with the available genome-wide DNA 
methylation data using the previously-published algorithm (Jaffe et al. 2015). For fetal samples, 
we used two independent fetal tissues which have both DNA methylation and RNA-seq datasets. 
(b) Editing rates normalized by glial proportion (c) Editing rates normalized by the neuronal 
proportion (d) Editing rates normalized by the ratio of neuronal  proportion to glial proportion. 
Normalization is simply done by dividing editing rates by the proportions. In b, c and d, lines 
indicate the five increasing clusters defined in figures 3.4 and 3.6 (The same colors and the same 
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numbers are used across the figures). Lines are generated by locally weighted scatterplot 















Figure 3.9. Editing rate differences among brain regions. A-to-I editing sites showing 
significant differences between cerebellum (CB) and other brain regions (DLPFC: dorsolateral 
prefrontal cortex, HIPPO: hippocampus, ERC: entorhinal cortex) are described. Each line 
corresponds to an editing site and the associated gene name is indicated. (a) Editing sites whose 
editing rates are higher in CB. (b) Editing sites with higher editing rates in neo cortical regions. 
Lines are generated by locally weighted scatterplot smoothing (loess) regression with 95% 















R5805 DLPFC 9.4 F CAUC Fetal -0.52 13 
R5807 DLPFC 9.8 M CAUC Fetal -0.52 13 
R5789 DLPFC 8.9 F CAUC Fetal -0.44 17 
R3404 DLPFC 8.4 M CAUC Fetal -0.42 18 
R5795 DLPFC 9.6 F CAUC Fetal -0.36 21 
R5815 DLPFC 9.5 M CAUC Fetal -0.35 22 
R3594 DLPFC 8.5 M CAUC Infant 0.33 57 
R3571 DLPFC 8.8 M CAUC Infant 0.35 58 
R3591 DLPFC 8.8 M CAUC Infant 0.36 59 
R3650 DLPFC 8.2 F CAUC Child 1.62 
NA 
R3547 DLPFC 8.1 F CAUC Child 2.49 
R3552 DLPFC 7.1 M CAUC Child 3.05 
R4699 DLPFC 8.7 M CAUC Child 4.14 
R4703 DLPFC 7.9 M CAUC Child 4.65 
R3545 DLPFC 7.9 M CAUC Child 4.71 
R5824 DLPFC 8.1 F CAUC Teen 16.65 
R3497 DLPFC 8.9 M CAUC Teen 16.93 
R3523 DLPFC 9.7 F CAUC Teen 17.24 
R3557 DLPFC 9 M CAUC Teen 18.12 
R3447 DLPFC 8.3 M CAUC Teen 18.42 
R4029 DLPFC 8.9 F CAUC Teen 18.76 
R4054 DLPFC 8.6 F CAUC Middle 40.61 
R2897 DLPFC 8.7 M CAUC Middle 41.04 
R4049 DLPFC 8.6 F CAUC Middle 41.20 
R4371 DLPFC 7.5 M CAUC Middle 41.78 
R3791 DLPFC 8.5 M CAUC Middle 42.07 
R2826 DLPFC 8.6 M CAUC Middle 42.84 
R3539 DLPFC 7.7 F CAUC Old 57.48 
R3479 DLPFC 8.1 M CAUC Old 58.61 
R3766 DLPFC 8.4 F CAUC Old 59.26 
R3445 DLPFC 8.2 M CAUC Old 61.17 
R4038 DLPFC 8.3 M CAUC Old 67.87 
R3990 DLPFC 8.5 F CAUC Old 71.11 
 
Table 3.1 Demographic details of the human brain tissues. RNA ID: sample identifier; 
Region: brain region, DLPFC (dorsolateral prefrontal cortex); RIN: RNA integrity number 
indicating RNA quality; Sex: M (male) or F (female); RACE: CAUC (Caucasian); Age Group: 
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six categories according to age, fetal (before birth), infant (birth to 12 months), child (1≤ age <10), 
teen (10≤ age <20), middle (20≤ age <50) and old life (age ≥ 50); Age: years old; Gestational 


















RNA ID Total number of reads Number of RNA editing sties 
R5805 80,337,568 25,567 
R5807 124,013,892 24,408 
R5789 115,578,312 49,525 
R3404 101,440,880 69,143 
R5795 135,185,718 72,255 
R5815 137,933,864 24,355 
R3594 115,856,986 93,553 
R3571 136,135,132 93,483 
R3591 155,835,950 86,731 
R3650 167,953,146 103,649 
R3547 93,909,690 61,348 
R3552 119,030,262 57,923 
R4699 95,116,394 69,460 
R4703 197,052,880 104,694 
R3545 122,085,850 76,074 
R5824 184,243,872 102,841 
R3497 107,834,650 65,739 
R3523 176,310,414 89,674 
R3557 100,916,134 62,852 
R3447 96,398,214 67,615 
R4029 186,789,930 91,690 
R4054 91,322,460 64,596 
R2897 93,746,042 47,099 
R4049 97,608,938 69,177 
R4371 105,055,680 70,288 
R3791 82,526,684 49,291 
R2826 118,781,082 73,717 
R3539 114,574,246 53,600 
R3479 87,319,298 43,724 
R3766 82,157,476 40,286 
R3445 93,543,730 58,576 
R4038 98,241,300 65,126 
R3990 149,259,434 65,025 
Average 120,124,124 66,457 
 




Type Number Proportion (%) 
A->G 134,914 81.0 
T->C 17,133 10.3 
G->A 3,192 1.9 
C->T 1,803 1.1 
C->A 1,219 0.7 
T->A 991 0.6 
G->T 824 0.5 
A->T 647 0.4 
G->C 528 0.3 
A->C 465 0.3 
T->G 457 0.3 
C->G 437 0.3 
Uncertain 3,915 2.3 
Total 166,525 100.0 
 
Table 3.3 Number of RNA editing sites in genic regions according to types 
 
 
Annotation Number Proportion (%) 
Total 134,914 100.0 
Intronic 109,411 81.1 
3' UTR 13,940 10.3 
CDS 282 0.2 
5' UTR 247 0.2 
ncRNA 11,034 8.2 
 





Table 3.5 A-to-I editing sites with increasing pattern See Appendix 1: Chromosome and  
Coordinate: location of A-to-I editing sites in UCSC human genome hg19; Strand, Gene and 
Gene region: gene annotation based on RefSeq; DB: whether a A-to-I editing site is found in 
RADAR(Ramaswami & Li 2014), a public A-to-I editing database; Prenatal mean, Post-infant 
mean, Mean difference (diff.), Cluster in Editing rate: summary of editing rates in 33 samples. 



















Neu. Ast. MO NFO OPC MG End. 
chr1:172092348 COPA CDS 0.05 0.22 0.07 0.28 0.49 0.55 0.48 
chr1:172074326 NCSTN CDS 0.01 0.00 0.00 0.00 0.00 0.02 0.01 
chr19:40327452 SORBS1 CDS 0.00 0.00 0.00 0.00 0.00 NA 0.00 
chr19:40327453 SORBS1 CDS 0.00 0.00 0.00 0.00 0.00 NA 0.00 
chr7:130759165 TACC2 CDS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
chr9:4456006 GRIA4 CDS 0.65 0.33 0.01 0.09 0.16 NA 0.25 
chr14:50919694 OSGEP CDS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
chr12:46700334 NOVA1 CDS 0.08 0.00 0.00 0.00 0.02 0.00 0.00 
chr9:57144307 NEIL1 CDS 0.03 0.00 0.00 0.00 0.00 0.00 0.00 
chr11:102479070 GPATCH8 CDS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
chr8:83661176 GIPC1 CDS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
chr8:83661088 GIPC1 CDS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
chr16:87940543 GRIK1 CDS 0.53 0.00 0.00 0.12 0.06 NA NA 
chr3:32561485 MFN1 CDS 0.33 0.01 0.00 0.00 0.01 0.00 0.00 
chr5:93189584 CCNI CDS 0.01 0.00 0.00 0.01 0.01 0.06 0.03 
chr3:80706908 GRIA2 CDS 0.28 0.08 0.05 0.06 0.07 0.00 0.00 
chr3:80692286 GRIA2 CDS 0.51 0.07 0.00 0.05 0.15 0.00 0.50 
chr17:45662949 TMEM63B CDS 0.45 0.01 0.00 0.02 0.05 0.00 0.01 
chr10:49272776 GRIK2 CDS 0.73 0.05 0.04 0.02 0.25 0.00 0.00 
chr10:49244347 GRIK2 CDS 0.10 0.00 0.00 0.00 0.00 NA 0.00 
chr10:49244330 GRIK2 CDS 0.88 0.05 0.00 0.04 0.19 NA 0.00 
chrX:150648527 TRO CDS 0.00 0.00 0.00 0.00 0.00 NA 0.00 
chrX:41654252 GRIA3 CDS 0.54 0.06 1.00 0.15 0.26 NA NA 
chr9:57144308 NEIL1 CDS 0.12 0.00 0.00 0.02 0.00 0.00 0.00 
chr3:80706912 GRIA2 CDS 0.97 0.67 0.67 0.84 0.99 1.00 1.00 
chr14:75719719 COG3 CDS 0.27 0.76 0.57 0.75 0.83 0.91 0.97 
 
Table 3.6 CDS-residing A-to-I editing sites in different mouse brain cell types. Site: location 
of A-to-I editing sites in UCSC mouse genome mm10. The A-to-I editing sites whose editing 
rates are greater than 0 in at least one cell type are marked by red; Gene and Gene region: gene 
annotation of A-to-I editing sites based on RefSeq; Columns 4 to 10: editing rates in Neuron 
(Neu.), Astrocyte (Ast.), Myelinating Oligodendrocyte (MO), Newly Formed Oligodendrocyte 
(NFO), Oligodendrocyte Precursor Cell (OPC), Microglia (MG), Endothelial cells (End.). Gray 
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indicates detected A-to-I editing rate. Yellow and green describe the highest and second-highest 




























R3715 DLPFC 7.3 F CAUC Fetal -0.40 19 poly-A 
R3390 DLPFC 9.9 M CAUC Fetal -0.40 19 poly-A 
R2855 DLPFC 8.5 
M CAUC Old 56.09 
NA 
Ribo-zero 
R4936 Hippocampus 8.3 Ribo-zero 
R10023 CB 7.9 Ribo-zero 
R10065 ERC 7.4 Ribo-zero 
R3395 DLPFC 8.9 
M CAUC Old 57.63 
Ribo-zero 
R5455 Hippocampus 8.6 Ribo-zero 
R10012 CB 7.4 Ribo-zero 
R10055 ERC 6 Ribo-zero 
R3766 DLPFC 8.4 
F CAUC Old 59.26 
Ribo-zero 
R4869 Hippocampus 8.1 Ribo-zero 
R10029 CB 7 Ribo-zero 
R10070 ERC 6 Ribo-zero 
R3052 DLPFC 7.3 
F CAUC Old 75.57 
Ribo-zero 
R4757 Hippocampus 7.7 Ribo-zero 
R10022 CB 7.3 Ribo-zero 
R10092 ERC 6 Ribo-zero 
R2839 DLPFC 8.3 
M CAUC Old 77.99 
Ribo-zero 
R4992 Hippocampus 8.2 Ribo-zero 
R10003 CB 7.6 Ribo-zero 
R10052 ERC 7 Ribo-zero 
 
Table 3.7 Additional brain samples. RNA ID: sample identifier; Region: brain region, DLPFC 
(dorsolateral prefrontal cortex), CB (cerebellum), HIPPO (hippocampus), ERC (entorhinal 
cortex); RIN: RNA integrity number indicating RNA quality; Sex: M (male) or F (female); 
RACE: CAUC (Caucasian); Age Group: fetal (before birth) and old life (age ≥ 40); Age: years 
old; Gestational week: age of fetal tissues represented by conventional week of pregnancy. RNA-








Mean editing rate 
CB DLPFC ERC HIPPO 
chr1:19544002 EMC1 3' UTR 0.29 0.65 0.59 0.56 
chr12:69237056 MDM2 3' UTR 0.53 0.31 0.25 0.28 
chr12:120899075 GATC 3' UTR 0.55 0.88 0.87 0.78 
chr12:132407137 ULK1 3' UTR 0.04 0.24 0.26 0.16 
chr13:20247023 MPHOSPH8 3' UTR 0.42 0.53 0.56 0.49 
chr14:70834087 SYNJ2BP 3' UTR 0.3 0.09 0.12 0.06 
chr17:3763779 CAMKK1 3' UTR 0.26 0.65 0.63 0.54 
chr17:17092596 MPRIP 3' UTR 0.43 0.25 0.17 0.28 
chr17:29861403 RAB11FIP4 3' UTR 0.22 0.33 0.42 0.33 
chr17:49042206 SPAG9 3' UTR 0.32 0.12 0.15 0.14 
chr17:79780692 FAM195B 3' UTR 0.31 0.75 0.67 0.56 
chr19:54487949 CACNG8 3' UTR 0.72 0.35 0.29 0.24 
chr2:176791181 KIAA1715 3' UTR 0.3 0.71 0.64 0.54 
chr2:201842411 FAM126B 3' UTR 0.61 0.21 0.18 0.23 
chr20:5175805 CDS2 3' UTR 0.04 0.15 0.17 0.14 
chr22:37765609 ELFN2 3' UTR 0 0.29 0.14 0.2 
chr3:119545199 GSK3B 3' UTR 0.15 0.36 0.37 0.34 
chr3:170181366 SLC7A14 3' UTR 0.49 0.28 0.22 0.25 
chr4:77979680 CCNI exonic 0.07 0.23 0.21 0.19 
chr4:89180382 PPM1K 3' UTR 0.13 0.31 0.39 0.36 
chr4:158281294 GRIA2 exonic 0.76 0.57 0.51 0.5 
chr6:102372572 GRIK2 exonic 0.05 0.38 0.41 0.3 
chr7:38764438 VPS41 3' UTR 0.59 0.33 0.29 0.29 
chr7:65619303 CRCP 3' UTR 0.32 0.09 0.09 0.1 
 
Table 3.8 A-to-I editing sites showing significant differences in editing rates among brain 
regions. Mean editing rates in 5 individuals. Site: location of A-to-I editing sites in UCSC human 
genome hg19; Gene and gene region: gene annotation of A-to-I editing sites based on RefSeq; 
Editing rates in DLPFC (dorsolateral prefrontal cortex), CB (cerebellum), HIPPO (hippocampus), 







Regulation of developmental A-to-I editing pattern 
 
In Chapter 3, I reported “the developmental A-to-I editing patterns”, comprising three distinct 
patterns across cortical development: “stable high”, “stable low” and “increasing”. In this chapter, 
I will demonstrate that these patterns are explained by the secondary structures of RNA and the 
temporal pattern of expression of ADAR enzymes and propose them as possible cis- and trans- 












4.1. Representative editing sites for developmental A-to-I editing 
pattern 
To compare three distinct A-to-I editing patterns in brain development, the sites that 
explicitly represent each pattern were selected. Here, I considered that ADAR enzymes can edit 
multiple adenosines in a target transcript. This characteristic of editing can blur differences 
among the three editing patterns especially when sites from different patterns are close to each 
other in their genomic coordinates. For example, there are some cases of increasingly-edited sites 
that are within a few bases from stable high-edited sites. This is likely due to incomplete 
efficiency of editing at the sites around a stable high-edited site in fetal samples, which generates 
seemingly increasingly-edited sites but truly passive byproducts around stable high editing. 
Therefore, I selected the representative sites for each pattern, which are spatially isolated from 
other patterns. The following three parameters are used to formulate conditions to select 
representative sites for each pattern: i) magnitude of increasing of editing rates from fetal to adult 
samples (parameter 1), ii) maximum editing rates (parameter 3) at the neighboring editing sites 
within a given distance (parameter 2). Specific conditions are as follows. From now on, the 
following labels were used for groups of selected sites representing each pattern: “Group I. Low”, 
“Group II. Increasing”, and “Group III. High”. 
 
Editing sites in “Group II. Increasing”: Representative sites for increasing pattern 
Sites representing the increasing pattern, which comprises ‘Group II. Increasing’, were 
chosen from the sites in figure 3.4 such that they have clear increasing pattern from fetal to adult 
ages and no stable high-edited sites are near increasingly-edited sites. These conditions were 
formalized by two quantitative requirements using the above three parameters: i) parameter 1 
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should be greater than a certain threshold, ii) parameter 3 should be less than a certain threshold 
for a given neighbor region specified by parameter 2. Currently we used 0.3, 800 bp, and 0.4 for 
the values of the parameters 1, 2 and 3, respectively. These values were determined 
systematically as follows: for parameter 2, I chose 800 bp to have an adequate number of sites for 
statistical tests (Figure 4.1a), considering that the number of selected sites decreases as parameter 
2 increases. I assumed that 800 bp is enough to check effects of neighboring sites. Parameters 1 
and 3 were chosen as conservatively as possible but keeping enough number of sites (Figure 4.1b). 
For parameter 1, 0.4 is too strict to identify enough sites, resulting in 0.3 being the choice. As for 
parameter 3, 0.4 is selected to maximize the number of selected sites. Using these conditions, a 
total of 58 sites were chosen for ‘Group II: Increasing’ (denoted by green in Figure 4.2). 
For all sites in group II except for 5 sites around DNA repeat regions, genotypes were 
checked in 12 selected samples covering fetal, infant and post-infant age groups in order to 
confirm that editing rates of about 50% after post-infant age are not affected by genomic variants. 
Specifically, a targeted DNA sequencing with extremely-high sequencing depth (mean: 5417 
reads, minimum: 113 reads) was performed for accurate genotyping. Table 4.1 showed that in 
three samples, for example, all the amplified sites are homozygous with reference alleles, 
confirming that sites in ‘Group II. Increasing’ are not genomic variants.  
 
Editing sites in “Group I. Low”: Representative sites for stable low patterns. 
For the stable low pattern, the sites were selected such that none of the stable high-edited 
and increasingly-edited sites are close to the stable low-edited sites. This was achieved by the 
conditions require that i) parameter 1 should be less than a certain threshold (0.1), ii) parameter 3 
should be less than a certain threshold (0.3) for a given parameter 2 (800), iii) sites should have 
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average editing rates greater than 0.1 and less than 0.3. As a result, ‘Group I: Low’ consists of 65 
selected sites for the stable low pattern (denoted by blue in Figure 4.2). 
 
Editing sites in “Group III. High”: Representative sites for stable high patterns. 
Here, the required conditions are i) parameter 1 should be less than a certain threshold 
(0.1), ii) sites should have average editing rates greater than 0.7. The 40 sites were selected for 
the stable high editing pattern and defined ‘Group III. High’ (denoted by red in Figure 4.2). 
To summarize, the selected sites comprise three groups each representing the three 
patterns respectively as follows: ‘Group I: Low’ consisting of 65 selected sites for the stable low 
pattern, ‘Group II: Increasing’ consisting of 58 selected sites for the increasing pattern and 




The expression levels of the known A-to-I editing enzymes across brain development 
were investigated as a potential trans-regulatory mechanism. There are two ADAR enzymes 
(ADAR1 and ADAR2) expressed in brain and known to be responsible for A-to-I RNA editing in 
humans. The expression level of ADARs was measured by RNA-seq with an RPKM (Reads Per 
Kilobase per Million) unit that is typically used for quantifying gene expression levels with RNA-
seq. The figure 4.3 showed that changes of expression of ADARs are correlated selectively with 
the developmentally-increasing A-to-I editing pattern. Specifically, the mean Spearman 
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correlation coefficients between ADAR mRNA levels and editing rates of the “Group II. 




For a potential cis-regulatory mechanism, the neighbor sequence preferences were first  
examined to compare the sensitivities to ADAR 1/2 among the three groups. There is no 
statistically significant difference in the frequency of 5’ and 3’ sequence preferences among the 
three groups, as all three groups share previously known 5’ and 3’ sequence preferences 
(Eggington et al. 2011) as T>A>C>G and G>C>A≈T respectively (Figure 4.4).  
Next, RNA secondary structure was considered as another cis-regulatory mechanism. 
Although ADARs are known to recognize the double-stranded structure of target RNAs, the 
subtle differences of RNA secondary-structures around editing sites may affect the efficiency of 
A-to-I editing. I developed quantitative measures of the degree and the distance of double-
stranded structure around A-to-I editing sites to compare the sensitivities of the three groups to 
ADAR 1/2 (see 4.4 methods). While the distance measure does not reveal significant differences 
(Figure 4.5), statistically-significant mean differences (ANOVA and post-hoc two-sample t-test) 
were observed in the degree of secondary structure among the three groups (Figure 4.6), where 
the group of increasingly-edited sites tend to have an intermediate degree of double stranded 
structure between the high and low editing sites. However, the high-edited sites have a broad 
range of degrees of double-stranded structure, which suggests additional or alternative regulatory 
mechanisms for these sites. In fact, evaluation of prior RNA-seq data from ADAR 1/2 
knockdown by siRNA in B-cells (I. X. Wang et al. 2013) showed that the high-edited sites are not 
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affected by ADAR 1/2 knockdown as much as the increasingly-edited sites (Figure 4.7 and Table 
4.3). Here, the effect of ADAR 1/2 knockdown for a given site is measured by the percent 
decrease of editing rate in ADAR siRNA-treated experiments compared to controls. These results 
suggest that the increasingly-edited sites are particularly dependent on ADAR 1/2 mechanisms. 
It is interesting to see these results from the perspective of a previously-proposed model 
of RNA editing. Previous studies (Daniel et al. 2012; Daniel et al. 2014) proposed that the long 
hairpin structure of RNA induces A-to-I editing by promoting the recruitment of ADAR enzymes 
to the transcript. This model, however, does not fully explain how different RNA editing rates are 
regulated. For example, A-to-I editing sites in Gabra3 and NEIL1 that were considered in a 
previous study (Daniel et al. 2014) as examples for the proposed model show two different 
editing patterns (increasing and stable-high, respectively) in brain development. The defined 
quantitative representation of double-stranded structure of RNAs may improve the model by 





For RNA-seq data obtained from previous studies, STAR (Dobin et al. 2013) is used for 
alignments. To estimate ADAR expression levels, RPKM (Reads Per Kilobase per Million) were 
calculated using HTSeq (Anders et al. 2014). 
 
Targeted DNA sequencing 
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This was done with the Fluidigm Access Array and the Illumina MiSeq through which 
PCR amplicons around target sites were generated on microfluidic chips and then sequenced. 
Only uniquely-mapped reads determined by BWA were used to determine genotypes. If a 
proportion of reference allele-supporting reads are greater than 90% of total sequencing reads at a 
site, its genotype is declared as homozygous with the reference allele. 
 
RNA secondary structure analyses 
The degree of double-stranded structure around and its distance from a given A-to-I 
editing site was calculated from computationally-predicted RNA-structure. First, RNA structure 
was predicted by RNAfold in Vienna RNA package 2.0 (Lorenz et al. 2011) using a pre-mRNA 
sequence spanning 800 bp upstream and downstream from a given editing site. Second, the 
number of nucleotides in a double-stranded configuration was counted within a flanking 100 bp 
region for every position on a pre-mRNA sequence. Finally, after the site associated with the 
maximum value within 500 bp upstream and downstream from an editing site was identified, the 
associated value was declared as the degree of double-stranded structure and the distance from 
the site to an editing site was called as the distance between a double-stranded structure and an 









Figure 4.1 Criteria for selecting the representative sites for the increasing A-to-I editing 
patterns. (a) As parameter 2 increases, the number of selected sites is decreasing for given 
parameters 1 and 3. Here, parameter 1 and 3 are 0.3 and 0.4, respectively. (b) For parameter 1 and 












Figure 4.2 Representative sites for developmental A-to-I editing patterns. Regression lines 
generated with the selected sites explicitly represent each pattern. Specifically, lines are generated 











Figure 4.3 ADAR expression across human brain development. mRNA expression levels of 











Figure 4.4 Sequence motif around A-to-I editing sites. (a) 5’ and 3’ sequence features flanking the sites in the three groups of selected sites, (b 
and c) Details of sequence frequency at 5’ and 3’ immediate neighbor respectively. Chi-Square test was performed to determine the significance of 




Figure 4.5 Distance between an editing site and a double-stranded structure. The groups 
were compared in terms of the distance between an editing site and a double-stranded structure, 
which is defined by the distance from an editing site to the site associated with the maximum 










Figure 4.6 Distribution of the degree of double-stranded structures (double-stranded degree) 
among the three groups of selected sites. The double-stranded degree represents the maximum 
number of local base-pairings around editing sites. *** and ** indicate p-value ≤0.001 and  p-











Figure 4.7 Effect of ADAR enzymes knockdown by siRNA in B-cells. The knockdown effect 
is defined by the percent decrease of editing rate in ADAR siRNA-treatments compared to 











Figure 4.8 Quantification of degree and distance of double-stranded structure around RNA-
editing sites. The degree of double-stranded structure for a given A-to-I editing site was 
calculated from computationally-predicted RNA-structure. First, RNA structure was predicted by 
RNAfold (rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) using a pre-mRNA sequence spanning 800 bp 
upstream and downstream from a given editing site. Second, the number of nucleotides in a 
double-stranded configuration was counted within a flanking 100 bp region for every position on 
a pre-mRNA sequence (moving-window search). In the figure, this is depicted by the rolling 
window of 5 nucleotides for simplicity. Finally, after the site associated with the maximum value 
within 500 bp upstream and downstream from an editing site was identified, the associated value 
was taken as the degree of double-stranded structure while the distance from the site to an editing 



































chr1:40147856 T 7707 7685 0.997 TT 4756 4746 0.998 TT 3546 3539 0.998 TT 
chr1:53289852 A 7894 7850 0.994 AA 7884 7854 0.996 AA 7871 7838 0.996 AA 
chr1:53291420 A 7994 7963 0.996 AA 7478 7452 0.997 AA 7995 7958 0.995 AA 
chr1:67874689 T 7994 7976 0.998 TT 7994 7980 0.998 TT 7987 7956 0.996 TT 
chr1:67874696 T 7992 7965 0.997 TT 7996 7967 0.996 TT 7985 7959 0.997 TT 
chr1:109748657 A 7787 7745 0.995 AA 7785 7739 0.994 AA 7804 7768 0.995 AA 
chr10:15120275 T 7975 7969 0.999 TT 6898 6895 1.000 TT 4984 4979 0.999 TT 
chr10:15120306 T 7980 7957 0.997 TT 6952 6945 0.999 TT 5013 5008 0.999 TT 
chr10:102777342 T 7994 7976 0.998 TT 7988 7971 0.998 TT 7884 7865 0.998 TT 
chr12:107280405 A 0 0 NA NA 0 0 NA NA 0 0 NA NA 
chr14:26917530 T 6618 6605 0.998 TT 3114 3109 0.998 TT 2393 2389 0.998 TT 
chr14:31916464 T 3877 3863 0.996 TT 2126 2126 1.000 TT 1308 1305 0.998 TT 
chr16:23476581 T 7964 7957 0.999 TT 7968 7951 0.998 TT 7960 7944 0.998 TT 
chr16:23477179 T 0 0 NA NA 0 0 NA NA 0 0 NA NA 
chr16:67715890 T 7961 7929 0.996 TT 7940 7914 0.997 TT 7922 7892 0.996 TT 
chr16:89630026 A 8004 7986 0.998 AA 7997 7981 0.998 AA 7018 7003 0.998 AA 
chr17:3763779 T 8005 7990 0.998 TT 4209 4203 0.999 TT 3294 3291 0.999 TT 
chr17:29862208 A 7985 7957 0.996 AA 7975 7946 0.996 AA 7987 7960 0.997 AA 
chr17:79780692 T 7962 7944 0.998 TT 7950 7931 0.998 TT 7950 7933 0.998 TT 
chr19:30191863 T 2579 2574 0.998 TT 1124 1121 0.997 TT 767 766 0.999 TT 
chr19:38887763 A 3919 3911 0.998 AA 3346 3332 0.996 AA 2070 2066 0.998 AA 
chr19:38888055 A 2251 2244 0.997 AA 787 787 1.000 AA 548 546 0.996 AA 
chr19:38889352 A 5076 5067 0.998 AA 3574 3563 0.997 AA 1980 1923 0.971 AA 
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chr2:172605884 A 8002 7989 0.998 AA 7676 7655 0.997 AA 5823 5817 0.999 AA 
chr2:176791181 T 7991 7957 0.996 TT 7998 7883 0.986 TT 7992 7962 0.996 TT 
chr2:176791182 T 7991 7971 0.997 TT 7993 7968 0.997 TT 7993 7971 0.997 TT 
chr2:176791183 T 7985 7956 0.996 TT 7996 7973 0.997 TT 7989 7967 0.997 TT 
chr2:202486541 T 7999 7980 0.998 TT 6933 6919 0.998 TT 5338 5329 0.998 TT 
chr20:5175539 A 7989 7985 0.999 AA 5163 5159 0.999 AA 3160 3158 0.999 AA 
chr21:30953750 T 8000 7972 0.997 TT 7022 6996 0.996 TT 5256 5236 0.996 TT 
chr21:44452594 A 0 0 NA NA 0 0 NA NA 0 0 NA NA 
chr3:10195096 A 2625 2617 0.997 AA 1392 1388 0.997 AA 1230 1227 0.998 AA 
chr4:100801747 T 7881 7832 0.994 TT 7866 7821 0.994 TT 7844 7805 0.995 TT 
chr4:158281294 A 7988 7945 0.995 AA 6723 6693 0.996 AA 4947 4931 0.997 AA 
chr5:68576744 T 5825 5819 0.999 TT 4113 4110 0.999 TT 3052 3048 0.999 TT 
chr5:156904831 T 7982 7931 0.994 TT 7978 7950 0.996 TT 7983 7956 0.997 TT 
chr5:156904853 T 7972 7959 0.998 TT 7977 7959 0.998 TT 7981 7959 0.997 TT 
chr5:156904922 T 7896 7862 0.996 TT 7897 7848 0.994 TT 7887 7850 0.995 TT 
chr5:156904950 T 7924 7903 0.997 TT 7915 7879 0.995 TT 7908 7872 0.995 TT 
chr5:156905396 T 7951 7881 0.991 TT 7944 7910 0.996 TT 7951 7897 0.993 TT 
chr5:156905398 T 7932 7909 0.997 TT 7934 7906 0.996 TT 7927 7904 0.997 TT 
chr5:156905405 T 7973 7949 0.997 TT 7966 7920 0.994 TT 7971 7918 0.993 TT 
chr5:156905560 T 7999 7964 0.996 TT 7999 7972 0.997 TT 7999 7958 0.995 TT 
chr6:18129214 T 7999 7969 0.996 TT 8000 7964 0.996 TT 8004 7947 0.993 TT 
chr6:52965317 A 0 0 NA NA 0 0 NA NA 0 0 NA NA 
chr6:90344222 T 7975 7926 0.994 TT 7976 7943 0.996 TT 7962 7935 0.997 TT 
chr6:90344571 T 386 382 0.990 TT 330 327 0.991 TT 325 320 0.985 TT 
chr6:90344605 T 385 385 1.000 TT 329 328 0.997 TT 324 322 0.994 TT 
chr6:90344706 T 385 385 1.000 TT 331 330 0.997 TT 323 323 1.000 TT 
chr6:102337702 A 7993 7978 0.998 AA 6698 6693 0.999 AA 6185 6181 0.999 AA 
78 
 
chr6:109784286 T 7965 7932 0.996 TT 7946 7914 0.996 TT 7374 7357 0.998 TT 
chr6:109784327 T 4489 4432 0.987 TT 3773 3747 0.993 TT 3069 3048 0.993 TT 
chr7:5662192 T 0 0 NA NA 0 0 NA NA 0 0 NA NA 
chr8:38828267 A 121 118 0.975 AA 158 154 0.975 AA 136 134 0.985 AA 
chr8:48889633 A 7983 7941 0.995 AA 7976 7952 0.997 AA 7977 7943 0.996 AA 
chr8:48890109 A 7996 7986 0.999 AA 8001 7990 0.999 AA 7989 7965 0.997 AA 
chrX:19931744 T 7992 7969 0.997 TT 7459 7445 0.998 TT 6676 6667 0.999 TT 
chrX:151358319 T 6097 6083 0.998 TT 3194 3193 1.000 TT 2918 2915 0.999 TT 
 
Table 4.1 Genotype confirmation of sites in Group II. Increasing. Among 12 samples genotyped, three samples are shown as examples. Site 
and Reference (Ref.): location and reference sequence at A-to-I editing sites in UCSC human genome hg19; Total read count, Reference (Ref.) 
read count, Reference (Ref.) read rate, Genotype in each sample: uniquely-mapped reads are counted. The numbers and the proportions of reads 
supporting the reference allele are described. If a proportion of reference allele-supporting reads are greater than 90% at a site, its genotype is 























chr1 1595586 SLC35E2B 
3' 
UTR 
0.822 0.889 0.800 -0.089 
Group III: 
High 
chr1 3730400 CEP104 
3' 
UTR 
0.770 0.712 0.788 0.076 
Group III: 
High 
chr1 36067817 PSMB2 
3' 
UTR 
0.903 0.831 0.927 0.095 
Group III: 
High 
chr1 36067886 PSMB2 
3' 
UTR 
0.735 0.676 0.757 0.081 
Group III: 
High 
chr1 226791920 C1orf95 
3' 
UTR 
0.710 0.755 0.691 -0.064 
Group III: 
High 
chr1 226793282 C1orf95 
3' 
UTR 
0.731 0.665 0.759 0.094 
Group III: 
High 
chr2 201843471 FAM126B 
3' 
UTR 
0.805 0.804 0.809 0.006 
Group III: 
High 
chr3 179115627 GNB4 
3' 
UTR 
0.859 0.792 0.867 0.075 
Group III: 
High 
chr4 17803019 DCAF16 
3' 
UTR 
0.725 0.729 0.737 0.008 
Group III: 
High 
chr4 17803537 DCAF16 
3' 
UTR 
0.969 0.961 0.972 0.011 
Group III: 
High 
chr4 158257875 GRIA2 CDS 0.927 0.928 0.921 -0.007 
Group III: 
High 
chr5 131287375 ACSL6 
3' 
UTR 
0.937 0.842 0.959 0.117 
Group III: 
High 
chr5 131289291 ACSL6 
3' 
UTR 
0.973 0.981 0.968 -0.012 
Group III: 
High 
chr6 158619523 GTF2H5 
3' 
UTR 
0.822 0.730 0.846 0.116 
Group III: 
High 
chr10 15118748 ACBD7 
3' 
UTR 
0.851 0.829 0.855 0.026 
Group III: 
High 
chr10 15118774 ACBD7 
3' 
UTR 
0.761 0.713 0.767 0.054 
Group III: 
High 
chr11 16778023 C11orf58 
3' 
UTR 
0.886 0.849 0.889 0.040 
Group III: 
High 
chr12 98942688 TMPO 
3' 
UTR 
0.885 0.811 0.905 0.094 
Group III: 
High 
chr12 98943033 TMPO 
3' 
UTR 








0.938 0.956 0.926 -0.030 
Group III: 
High 
chr12 120899011 GATC 
3' 
UTR 
0.876 0.823 0.896 0.073 
Group III: 
High 
chr13 50487444 SPRYD7 
3' 
UTR 





chr15 75646086 NEIL1 CDS 0.931 0.928 0.931 0.004 
Group III: 
High 
chr15 90375494 AP3S2 
3' 
UTR 
0.937 0.896 0.949 0.053 
Group III: 
High 
chr15 90375568 AP3S2 
3' 
UTR 
0.759 0.781 0.760 -0.020 
Group III: 
High 
chr15 90375859 AP3S2 
3' 
UTR 
0.840 0.818 0.850 0.032 
Group III: 
High 
chr17 2320651 METTL16 
3' 
UTR 
0.837 0.795 0.846 0.051 
Group III: 
High 
chr17 49042252 SPAG9 
3' 
UTR 
0.916 0.826 0.938 0.112 
Group III: 
High 
chr19 4654380 TNFAIP8L1 
3' 
UTR 
0.703 0.650 0.717 0.067 
Group III: 
High 
chr19 10742170 SLC44A2 CDS 0.703 0.819 0.704 -0.115 
Group III: 
High 
chr19 13883381 MRI1 
3' 
UTR 
0.857 0.843 0.859 0.015 
Group III: 
High 
chr19 39981298 TIMM50 
3' 
UTR 
0.966 0.938 0.972 0.033 
Group III: 
High 
chr19 40537196 ZNF780B 
3' 
UTR 
0.716 0.712 0.721 0.009 
Group III: 
High 
chr19 54488967 CACNG8 
3' 
UTR 
0.723 0.712 0.726 0.014 
Group III: 
High 
chr20 3851209 MAVS 
3' 
UTR 
0.919 0.910 0.916 0.006 
Group III: 
High 
chr20 43706947 STK4 
3' 
UTR 
0.829 0.839 0.820 -0.019 
Group III: 
High 
chr21 34636361 IFNAR2 
3' 
UTR 
0.917 0.834 0.935 0.102 
Group III: 
High 
chr21 34636384 IFNAR2 
3' 
UTR 
0.950 0.974 0.944 -0.031 
Group III: 
High 
chr22 18572675 PEX26 
3' 
UTR 
0.894 0.831 0.910 0.080 
Group III: 
High 
chrX 118672671 CXorf56 
3' 
UTR 
0.710 0.677 0.719 0.042 
Group II: 
Increasing 
chr1 40147856 HPCAL4 
3' 
UTR 
0.345 0.067 0.412 0.345 
Group II: 
Increasing 
chr1 53289852 ZYG11B 
3' 
UTR 
0.395 0.056 0.488 0.432 
Group II: 
Increasing 
chr1 53291420 ZYG11B 
3' 
UTR 
0.547 0.130 0.653 0.523 
Group II: 
Increasing 
chr1 67874689 SERBP1 
3' 
UTR 
0.679 0.128 0.818 0.690 
Group II: 
Increasing 
chr1 67874696 SERBP1 
3' 
UTR 
0.308 0.034 0.379 0.345 
Group II: 
Increasing 
chr1 109748657 KIAA1324 
3' 
UTR 
0.600 0.240 0.689 0.449 
Group II: 
Increasing 
chr2 172605884 DYNC1I2 
3' 
UTR 





chr2 176791181 KIAA1715 
3' 
UTR 
0.350 0.028 0.449 0.421 
Group II: 
Increasing 
chr2 176791182 KIAA1715 
3' 
UTR 
0.505 0.109 0.613 0.503 
Group II: 
Increasing 
chr2 176791183 KIAA1715 
3' 
UTR 
0.265 0.018 0.345 0.327 
Group II: 
Increasing 
chr2 202486541 TMEM237 
3' 
UTR 
0.282 0.025 0.352 0.327 
Group II: 
Increasing 
chr3 10195096 VHL 
3' 
UTR 
0.391 0.134 0.454 0.320 
Group II: 
Increasing 
chr4 100801747 LAMTOR3 
3' 
UTR 
0.704 0.215 0.823 0.608 
Group II: 
Increasing 
chr4 158281294 GRIA2 CDS 0.477 0.166 0.554 0.388 
Group II: 
Increasing 
chr5 68576744 CCDC125 
3' 
UTR 
0.304 0.034 0.379 0.345 
Group II: 
Increasing 
chr5 156904831 ADAM19 
3' 
UTR 
0.538 0.040 0.675 0.635 
Group II: 
Increasing 
chr5 156904853 ADAM19 
3' 
UTR 
0.279 0.016 0.360 0.344 
Group II: 
Increasing 
chr5 156904922 ADAM19 
3' 
UTR 
0.368 0.112 0.443 0.331 
Group II: 
Increasing 
chr5 156904950 ADAM19 
3' 
UTR 
0.304 0.039 0.381 0.342 
Group II: 
Increasing 
chr5 156905396 ADAM19 
3' 
UTR 
0.422 0.084 0.512 0.427 
Group II: 
Increasing 
chr5 156905398 ADAM19 
3' 
UTR 
0.370 0.015 0.450 0.435 
Group II: 
Increasing 
chr5 156905405 ADAM19 
3' 
UTR 
0.308 0.033 0.377 0.344 
Group II: 
Increasing 
chr5 156905560 ADAM19 
3' 
UTR 
0.493 0.111 0.609 0.497 
Group II: 
Increasing 
chr6 18129214 TPMT 
3' 
UTR 
0.401 0.008 0.515 0.507 
Group II: 
Increasing 
chr6 52965317 FBXO9 
3' 
UTR 
0.349 0.025 0.443 0.419 
Group II: 
Increasing 
chr6 90344222 LYRM2 
3' 
UTR 
0.586 0.122 0.716 0.594 
Group II: 
Increasing 
chr6 90344571 LYRM2 
3' 
UTR 
0.348 0.037 0.425 0.388 
Group II: 
Increasing 
chr6 90344605 LYRM2 
3' 
UTR 
0.393 0.104 0.473 0.369 
Group II: 
Increasing 
chr6 90344706 LYRM2 
3' 
UTR 
0.266 0.045 0.324 0.279 
Group II: 
Increasing 
chr6 102337702 GRIK2 CDS 0.645 0.216 0.758 0.542 
Group II: 
Increasing 
chr6 109784286 ZBTB24 
3' 
UTR 
0.443 0.159 0.508 0.349 
Group II: 
Increasing 
chr6 109784327 ZBTB24 
3' 
UTR 





chr7 5662192 RNF216 
3' 
UTR 
0.340 0.059 0.426 0.367 
Group II: 
Increasing 
chr8 38828267 PLEKHA2 
3' 
UTR 
0.327 0.040 0.387 0.346 
Group II: 
Increasing 
chr8 48889633 MCM4 
3' 
UTR 
0.480 0.100 0.586 0.485 
Group II: 
Increasing 
chr8 48890109 MCM4 
3' 
UTR 
0.659 0.182 0.786 0.605 
Group II: 
Increasing 
chr10 15120275 ACBD7 
3' 
UTR 
0.458 0.139 0.546 0.406 
Group II: 
Increasing 
chr10 15120306 ACBD7 
3' 
UTR 
0.324 0.118 0.376 0.258 
Group II: 
Increasing 
chr10 102777342 PDZD7 CDS 0.613 0.144 0.734 0.590 
Group II: 
Increasing 
chr12 107280405 RIC8B 
3' 
UTR 
0.391 0.067 0.488 0.421 
Group II: 
Increasing 
chr14 26917530 NOVA1 CDS 0.245 0.015 0.309 0.294 
Group II: 
Increasing 
chr14 31916464 DTD2 
3' 
UTR 
0.496 0.182 0.577 0.394 
Group II: 
Increasing 
chr16 23476581 GGA2 
3' 
UTR 
0.683 0.213 0.803 0.590 
Group II: 
Increasing 
chr16 23477179 GGA2 
3' 
UTR 
0.310 0.077 0.380 0.304 
Group II: 
Increasing 
chr16 67715890 GFOD2 
3' 
UTR 
0.452 0.111 0.538 0.427 
Group II: 
Increasing 
chr16 89630026 RPL13 
3' 
UTR 
0.515 0.141 0.626 0.484 
Group II: 
Increasing 
chr17 3763779 CAMKK1 
3' 
UTR 
0.483 0.069 0.608 0.539 
Group II: 
Increasing 
chr17 29862208 RAB11FIP4 
3' 
UTR 
0.535 0.162 0.629 0.466 
Group II: 
Increasing 
chr17 79780692 FAM195B 
3' 
UTR 
0.526 0.069 0.655 0.586 
Group II: 
Increasing 
chr19 30191863 C19orf12 
3' 
UTR 
0.357 0.100 0.419 0.319 
Group II: 
Increasing 
chr19 38887763 SPRED3 
3' 
UTR 
0.249 0.047 0.306 0.259 
Group II: 
Increasing 
chr19 38888055 SPRED3 
3' 
UTR 
0.360 0.050 0.452 0.402 
Group II: 
Increasing 
chr19 38889352 SPRED3 
3' 
UTR 
0.340 0.032 0.422 0.390 
Group II: 
Increasing 
chr20 5175539 CDS2 
3' 
UTR 
0.327 0.040 0.406 0.366 
Group II: 
Increasing 
chr21 30953750 GRIK1 CDS 0.517 0.130 0.599 0.469 
Group II: 
Increasing 
chr21 44452594 PKNOX1 
3' 
UTR 
0.283 0.040 0.346 0.305 
Group II: 
Increasing 
chrX 19931744 CXorf23 
3' 
UTR 





chrX 151358319 GABRA3 CDS 0.694 0.201 0.804 0.603 
Group I: 
Low 
chr1 20978457 DDOST 
3' 
UTR 
0.131 0.230 0.108 -0.122 
Group I: 
Low 
chr1 109474780 CLCC1 
3' 
UTR 
0.184 0.148 0.191 0.043 
Group I: 
Low 
chr1 160112527 ATP1A2 
3' 
UTR 
0.143 0.171 0.142 -0.029 
Group I: 
Low 
chr1 179070646 ABL2 
3' 
UTR 
0.179 0.188 0.174 -0.014 
Group I: 
Low 
chr2 102508477 MAP4K4 
3' 
UTR 
0.110 0.109 0.108 -0.001 
Group I: 
Low 
chr2 166730667 TTC21B 
3' 
UTR 
0.131 0.062 0.157 0.095 
Group I: 
Low 
chr3 49452787 TCTA 
3' 
UTR 
0.108 0.143 0.105 -0.038 
Group I: 
Low 
chr3 101545798 NXPE3 
3' 
UTR 
0.134 0.120 0.138 0.018 
Group I: 
Low 
chr3 155480786 C3orf33 
3' 
UTR 
0.171 0.172 0.180 0.008 
Group I: 
Low 
chr4 7059305 TADA2B 
3' 
UTR 
0.109 0.085 0.118 0.033 
Group I: 
Low 
chr4 166000148 TMEM192 
3' 
UTR 
0.136 0.068 0.153 0.085 
Group I: 
Low 
chr6 42175084 MRPS10 
3' 
UTR 
0.107 0.126 0.104 -0.022 
Group I: 
Low 
chr6 42175097 MRPS10 
3' 
UTR 
0.103 0.098 0.106 0.008 
Group I: 
Low 
chr7 65618305 CRCP 
3' 
UTR 
0.141 0.148 0.139 -0.009 
Group I: 
Low 
chr7 65618306 CRCP 
3' 
UTR 
0.136 0.134 0.138 0.004 
Group I: 
Low 
chr7 65618332 CRCP 
3' 
UTR 
0.101 0.089 0.103 0.013 
Group I: 
Low 
chr7 73150707 ABHD11 
3' 
UTR 
0.121 0.163 0.110 -0.054 
Group I: 
Low 
chr7 73646106 RFC2 
3' 
UTR 
0.137 0.122 0.142 0.020 
Group I: 
Low 
chr7 73646121 RFC2 
3' 
UTR 
0.112 0.100 0.116 0.016 
Group I: 
Low 
chr7 73646147 RFC2 
3' 
UTR 
0.145 0.144 0.148 0.004 
Group I: 
Low 
chr7 73646229 RFC2 
3' 
UTR 
0.130 0.089 0.141 0.052 
Group I: 
Low 
chr7 92166602 RBM48 
3' 
UTR 
0.115 0.135 0.110 -0.024 
Group I: 
Low 
chr7 102089037 ORAI2 
3' 
UTR 
0.123 0.114 0.125 0.011 
Group I: 
Low 
chr7 102090451 ORAI2 
3' 
UTR 





chr8 42884354 HOOK3 
3' 
UTR 
0.152 0.081 0.172 0.091 
Group I: 
Low 
chr8 42884422 HOOK3 
3' 
UTR 
0.112 0.116 0.114 -0.003 
Group I: 
Low 
chr8 42884423 HOOK3 
3' 
UTR 
0.162 0.119 0.174 0.054 
Group I: 
Low 
chr8 104411941 SLC25A32 
3' 
UTR 
0.112 0.107 0.115 0.008 
Group I: 
Low 
chr9 132590069 C9orf78 
3' 
UTR 
0.105 0.085 0.104 0.019 
Group I: 
Low 
chr10 82192318 FAM213A 
3' 
UTR 
0.172 0.204 0.166 -0.038 
Group I: 
Low 
chr10 82282216 TSPAN14 
3' 
UTR 
0.102 0.064 0.110 0.046 
Group I: 
Low 
chr10 126451032 METTL10 CDS 0.143 0.085 0.154 0.069 
Group I: 
Low 
chr11 8707840 RPL27A 
3' 
UTR 
0.153 0.153 0.156 0.003 
Group I: 
Low 
chr11 61567700 FADS1 
3' 
UTR 
0.103 0.099 0.105 0.006 
Group I: 
Low 
chr11 63724420 NAA40 
3' 
UTR 
0.136 0.048 0.159 0.111 
Group I: 
Low 
chr11 111653930 ALG9 
3' 
UTR 
0.125 0.110 0.135 0.025 
Group I: 
Low 
chr12 54629209 CBX5 
3' 
UTR 
0.115 0.098 0.116 0.019 
Group I: 
Low 
chr13 46090371 COG3 CDS 0.106 0.031 0.120 0.090 
Group I: 
Low 
chr14 23303976 MRPL52 
3' 
UTR 
0.228 0.150 0.244 0.094 
Group I: 
Low 
chr16 28976933 NFATC2IP 
3' 
UTR 
0.108 0.127 0.098 -0.029 
Group I: 
Low 
chr16 69390514 TERF2 
3' 
UTR 
0.125 0.104 0.125 0.021 
Group I: 
Low 
chr16 70407018 DDX19A 
3' 
UTR 
0.133 0.121 0.134 0.013 
Group I: 
Low 
chr16 70413821 ST3GAL2 
3' 
UTR 
0.118 0.130 0.110 -0.020 
Group I: 
Low 
chr17 1368284 MYO1C 
3' 
UTR 
0.106 0.119 0.096 -0.023 
Group I: 
Low 
chr17 1368288 MYO1C 
3' 
UTR 
0.105 0.118 0.097 -0.020 
Group I: 
Low 
chr17 20217878 SPECC1 
3' 
UTR 
0.134 0.057 0.151 0.094 
Group I: 
Low 
chr17 20217935 SPECC1 
3' 
UTR 
0.132 0.073 0.154 0.081 
Group I: 
Low 
chr17 25640011 WSB1 
3' 
UTR 
0.106 0.107 0.107 0.000 
Group I: 
Low 
chr17 28513019 NSRP1 
3' 
UTR 





chr18 11882606 GNAL 
3' 
UTR 
0.149 0.101 0.166 0.065 
Group I: 
Low 
chr19 5206255 PTPRS 
3' 
UTR 
0.111 0.167 0.108 -0.058 
Group I: 
Low 
chr19 40022726 EID2B 
3' 
UTR 
0.107 0.085 0.115 0.030 
Group I: 
Low 
chr19 41828971 CCDC97 
3' 
UTR 
0.119 0.033 0.135 0.102 
Group I: 
Low 
chr19 58774627 ZNF544 
3' 
UTR 
0.134 0.093 0.150 0.057 
Group I: 
Low 
chr20 3805458 AP5S1 
3' 
UTR 
0.109 0.214 0.083 -0.132 
Group I: 
Low 
chr20 3805459 AP5S1 
3' 
UTR 
0.200 0.286 0.171 -0.115 
Group I: 
Low 
chr20 3805511 AP5S1 
3' 
UTR 
0.146 0.129 0.153 0.024 
Group I: 
Low 
chr20 3853956 MAVS 
3' 
UTR 
0.115 0.088 0.129 0.041 
Group I: 
Low 
chr20 3853967 MAVS 
3' 
UTR 
0.165 0.124 0.184 0.060 
Group I: 
Low 
chr20 3854106 MAVS 
3' 
UTR 
0.145 0.108 0.159 0.051 
Group I: 
Low 
chr21 34728113 IFNAR1 
3' 
UTR 
0.124 0.079 0.124 0.045 
Group I: 
Low 
chr21 34728136 IFNAR1 
3' 
UTR 
0.133 0.190 0.109 -0.081 
Group I: 
Low 
chr21 37666181 DOPEY2 
3' 
UTR 
0.122 0.106 0.125 0.019 
Group I: 
Low 
chr22 21244926 SNAP29 
3' 
UTR 
0.104 0.133 0.099 -0.034 
Group I: 
Low 
chrX 123044597 XIAP 
3' 
UTR 
0.112 0.058 0.129 0.070 
 
Table 4.2 The representative sites for developmental A-to-I editing patterns. Group: a pattern 
that a site represents, corresponding to figure 4.2; Chromosome and  Coordinate: location of A-
to-I editing sites in UCSC human genome hg19; Gene and Gene region: gene annotation based on 
RefSeq; Mean, Prenatal mean, Post-infant mean and Mean difference (diff.) in Editing rate: 





Site Group Depth 












High 138 0.78 0.56 0.74 0.29 0.06 
chr1:3730400 
Group III: 
High 54 0.93 0.22 0.84 0.76 0.10 
chr1:36067817 
Group III: 
High 449 0.82 0.40 0.80 0.51 0.02 
chr1:36067886 
Group III: 
High 320 0.75 0.51 0.81 0.32 -0.09 
chr2:201843471 
Group III: 
High 43 0.88 0.67 0.76 0.25 0.14 
chr4:17803019 
Group III: 
High 55 0.80 0.59 0.72 0.27 0.10 
chr4:17803537 
Group III: 
High 44 0.84 0.72 0.98 0.15 -0.16 
chr12:98942688 
Group III: 
High 243 0.93 0.50 0.92 0.46 0.01 
chr12:98943033 
Group III: 
High 262 0.93 0.72 0.97 0.22 -0.05 
chr12:117014187 
Group III: 
High 41 0.98 1.00 1.00 -0.03 -0.03 
chr12:120899011 
Group III: 
High 277 0.89 0.51 0.87 0.42 0.02 
chr13:50487444 
Group III: 
High 34 0.76 0.40 0.76 0.48 0.00 
chr15:90375494 
Group III: 
High 44 0.96 0.74 0.91 0.22 0.05 
chr15:90375568 
Group III: 
High 46 0.78 0.63 0.83 0.19 -0.05 
chr15:90375859 
Group III: 
High 45 0.86 0.38 0.78 0.56 0.09 
chr17:2320651 
Group III: 
High 134 0.75 0.37 0.72 0.50 0.04 
chr17:49042252 
Group III: 
High 70 0.94 0.49 0.78 0.48 0.16 
chr19:4654380 
Group III: 
High 120 0.74 0.26 0.72 0.65 0.04 
chr19:10742170 
Group III: 
High 399 0.52 0.49 0.47 0.06 0.09 
chr19:13883381 
Group III: 
High 99 0.98 0.58 0.84 0.41 0.15 
chr19:39981298 
Group III: 
High 42 1.00 0.32 0.98 0.68 0.02 
chr19:40537196 
Group III: 
High 32 0.66 0.37 0.54 0.43 0.17 
chr20:3851209 
Group III: 





High 728 0.61 0.40 0.62 0.35 0.00 
chr21:34636361 
Group III: 
High 371 0.65 0.21 0.69 0.68 -0.06 
chr21:34636384 
Group III: 
High 357 0.86 0.51 0.88 0.41 -0.03 
chr22:18572675 
Group III: 
High 352 0.68 0.32 0.77 0.52 -0.14 
chrX:118672671 
Group III: 
High 119 0.68 0.26 0.66 0.61 0.03 
chr1:53289852 
Group II: 
Inc. 32 0.31 0.00 0.14 1.00 0.55 
chr1:53291420 
Group II: 
Inc. 75 0.31 0.08 0.40 0.75 -0.30 
chr1:67874689 
Group II: 
Inc. 225 0.68 0.03 0.72 0.95 -0.06 
chr1:67874696 
Group II: 
Inc. 232 0.26 0.00 0.28 0.99 -0.08 
chr2:176791181 
Group II: 
Inc. 30 0.30 0.00 0.09 1.00 0.71 
chr2:176791182 
Group II: 
Inc. 30 0.33 0.00 0.18 1.00 0.47 
chr3:10195096 
Group II: 
Inc. 93 0.62 0.04 0.45 0.93 0.28 
chr4:100801747 
Group II: 
Inc. 41 0.39 0.00 0.49 1.00 -0.26 
chr5:68576744 
Group II: 
Inc. 59 0.24 0.00 0.17 1.00 0.26 
chr5:156904831 
Group II: 
Inc. 182 0.22 0.03 0.14 0.86 0.36 
chr5:156904922 
Group II: 
Inc. 129 0.29 0.03 0.14 0.91 0.53 
chr5:156904950 
Group II: 
Inc. 147 0.12 0.00 0.08 1.00 0.39 
chr5:156905396 
Group II: 
Inc. 119 0.20 0.03 0.26 0.85 -0.31 
chr5:156905560 
Group II: 
Inc. 145 0.35 0.03 0.40 0.92 -0.16 
chr6:90344222 
Group II: 
Inc. 67 0.51 0.11 0.42 0.78 0.17 
chr6:90344605 
Group II: 
Inc. 77 0.31 0.00 0.20 1.00 0.37 
chr6:90344706 
Group II: 
Inc. 67 0.22 0.00 0.21 1.00 0.06 
chr6:109784286 
Group II: 
Inc. 99 0.27 0.01 0.22 0.96 0.16 
chr6:109784327 
Group II: 
Inc. 104 0.41 0.00 0.50 1.00 -0.22 
chr8:38828267 
Group II: 





Inc. 481 0.13 0.01 0.09 0.89 0.34 
chr8:48890109 
Group II: 
Inc. 479 0.27 0.02 0.23 0.92 0.16 
chr14:31916464 
Group II: 
Inc. 79 0.59 0.05 0.63 0.92 -0.06 
chr16:23476581 
Group II: 
Inc. 250 0.35 0.02 0.38 0.94 -0.07 
chr16:67715890 
Group II: 
Inc. 23 0.31 0.00 0.22 1.00 0.29 
chr16:89630026 
Group II: 
Inc. 154 0.31 0.01 0.34 0.97 -0.09 
chr19:30191863 
Group II: 
Inc. 26 0.35 0.00 0.18 1.00 0.49 
chr20:5175539 
Group II: 
Inc. 69 0.25 0.06 0.23 0.78 0.07 
 
Table 4.3 Effect of ADAR knock down (KD) by siRNA on developmental A-to-I editing 
patterns. Site: location of A-to-I editing sites in UCSC human genome hg19; Group: a pattern 
that a site represents, corresponding to figure 4.2, ‘Group II: Inc.’ stands for ‘Group II. 
Increasing’; Depth: minimum sequencing depth among control, ADAR1 KD, ADAR2 KD RNA-
seq experiments; Editing rate and Knock down effect: The knock down effect for a given site is 












Functional implications of increasing A-to-I editing pattern 
 
In this chapter, I explore the functional implications of the developmental A-to-I editing patterns. 
First, I report that the increasing editing pattern is much less apparent in other organ tissues and is 
conserved in mouse brain development, highlighting the importance of the increasing pattern in 
the nervous system. Second, the increasing editing pattern is analyzed at the cellular level with 
the differentiating human and mouse embryonic stem cells, which reveals its temporal association 
with the growth of cortical layers and neuronal maturation. Gene Ontology (GO) analyses 
implicate genes with the increasing A-to-I editing pattern in vesicle/organelle membrane and 
glutamate signaling pathways. Third, possible roles of the increasing editing pattern are presented 
at a molecular level. The computational analyses show that editing rates are correlated with gene 
expression levels and have potential to affect miRNA-binding. Finally, I demonstrate that the 
increasing editing pattern involves genes associated with neurodevelopmental disorders and is 








5.1. Tissue variation of the increasing editing pattern 
In order to explore the functional implications of the developmental A-to-I editing 
patterns, I first investigated how the three patterns manifest in other human tissues, using 
available RNA-seq datasets (see section 5.6 Methods). Editing rates at the sites showing the 
increasing pattern in brain were compared across brain, heart and liver, each consisting of one 
fetal and one adult sample. It should be noted that here independent brain samples were used 
from the initial 33 discovery brain tissues, which allows further validation of the patterns. 
Interestingly, the brain shows the clearest separation of the three editing patterns, with the 
increasing editing pattern found principally in brain (Figure. 5.1a), and with very little of the 
increasing pattern in heart (Figure. 5.1b) and less in liver (Figure. 5.1c). In contrast, high-edited 
sites and low-edited sites show similar editing rates in fetus and adult regardless of tissue types. 
This analysis was extended to a total of 6 different organ tissues with multiple fetal and adult 
samples in every tissue (Figure. 5.2). Brain tissue has again the most significant distinction of the 
increasing A-to-I editing pattern (ANOVA and post-hoc two-sample t-test). It turned out that only 
brain tissue has higher expression levels of both ADAR1 and ADAR2 in adult samples compared 
to fetal samples (Figure. 5.3). In short, the increasing pattern of RNA editing, though found to a 
small degree in some other tissues, is strongest in brain tissue, at least at these specific A-to-I 
editing sites we found changing across brain development.  But it is also confirmed that some 
other tissues have their own set of sites showing a developmentally increasing editing pattern (see 
5.6 Methods, Figure 5.4). Specifically, lung and liver also show relative enrichment of 
increasingly-edited sites, compared to heart and muscle. But the sites showing an increasing 
editing pattern in these tissues are mostly different in each tissue and for the most part not the 
same as those in brain (Figure 5.5). Therefore, it should be noted that the discovery of the A-to-I 
editing sites showing the increasing pattern in brain development does not mean that increasing 
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editing patterns per se are unique to brain. Increasing patterns might be seen in the development 
of different organs at different editing sites. 
 
 
5.2. The increasing editing pattern in mouse brain development 
Available mouse RNA-seq data (Sauvageau et al. 2013; Fertuzinhos et al. 2014) were 
also surveyed to see if the increasing A-to-I editing pattern in human brain development is 
conserved in mouse brain development. Among 742 A-to-I editing sites showing the increasing 
pattern in human brain, 95 sites are found to be conserved in the  mouse genome (Table 5.1). The 
64 sites with adequate sequencing depth (median depth≥20) were investigated and a similar 
increasing pattern was mainly found at the sites in CDS regions (Figures 5.6 and 5.7 with Table 
5.2). As expected, this increasing is correlated with mouse ADAR expression levels, especially 
for ADAR2 (Figure 5.8). One exceptional site in a CDS, showing marked loss of the increasing 
pattern, is the editing site in NEIL1, which may be understood in terms of Alu repeats in the 
human genome. The Alu repeats neighboring this site form long double-stranded structures 
(Figure 5.9) and are believed to induce RNA editing only in human tissues (Daniel et al. 2014). 
These results show that although the number of editing sites showing the increasing pattern is 
relatively limited in mouse, the pattern itself is conserved in both human and mouse brain 
development. 
But it should be also noted that sites with increasing pattern that is found only in human 
genome, not in model organisims such as mouse, are likely human or primate-specific editing 
sites with potential functionalities. One possible example is the novel RNA editing site in PDZD7 
(PDZ-domain containing protein 7). This site has a developmentally-increasing editing rate and 
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causes the loss of a stop codon (UAG to UGG) in the gene isoform specific to humans (Figure 
5.10). In fact, PDZD7, a scaffolding protein implicated in Usher syndrome is known to be 
involved in the cilia compartment which is important in the developing brain (Sarkisian & 
Guadiana 2015; Valente et al. 2013).  
 
 
5.3. Cellular understanding of the increasing editing pattern  
The relative brain-selectivity of the evolutionary-conserved developmentally-increasing 
A-to-I editing pattern implies a potentially unique functional role in the nervous system. To 
explore this possibility at a cellular level, I investigated in-vitro differentiation of human and 
mouse embryonic stem cells (hESCs and mESCs) into cortical neurons from available RNA-seq 
datasets (van de Leemput et al. 2014; Hubbard et al. 2013). Although the amount of increasing is 
modest compared to the post-mortem brain samples (Figure 5.11), I confirmed similar increasing 
patterns of A-to-I editing such that the relative differences within the increasing pattern found in 
brain tissues are replicated in the in-vitro corticogenesis with hESCs, as marked by the matching 
numbers between figure 3.4 (also in figure 3.6) and figure 5.12. The in-vitro differentiation of 
mouse ESCs shows the increasing pattern more clearly (Figure 5.13). This in-vitro recapitulation 
of the increasing pattern enables us to annotate a developmental stage manifesting this pattern. 
Specifically, the increasing pattern appears to occur coincidentally with deep cortical layer (DL) 
formation after cortical speciation (CS) according to previously-defined cellular phenotypes as 
shown in a top bar in figure. 5.12 (van de Leemput et al. 2014). Indeed, it correlates with 
expression of a deep cortical layer marker, TBR1 and an axon marker, MAPT (Figure 5.14), 
showing that cortical layer development with neuronal maturation may be a specific period 
involving the emergence of the increasing RNA editing pattern. The relevance for neuronal 
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maturation is further supported by the change in editing rate found in primary culture of mouse 
neurons (Figure 5.15). A reanalysis of the previous data (Rybak-Wolf et al. 2015) reveals that the 
editing rates are increasing as early neurons mature with the increasing expression of synaptic 
markers such as SYN1 and SYN2 (Figure 5.16). These results are also consistent with the 
observation from in-vivo mouse brain tissues (Figure 5.6) where the increasing pattern emerges in 
embryonic day 15 to 18 and continues into early post-natal days, a period characterized by 
cortical layer expansion and neuronal maturation.   
The GO terms associated with genes showing the increasing RNA editing pattern (Figure 
5.17 and Table 5.3), such as glutamate signaling and organelle or vesicle-related transport, are 
cellular processes known to be active during cortical circuit development that we highlight. For 
example, glutamate signaling participates in neuronal migration in cortex (Luhmann et al. 2015) 
and also stimulates the growth of functional spines in developing cortex (Kwon & Sabatini 2011). 
Organelles and vesicles are critical in regulating neuronal morphogenesis including neurite 
growth and synaptic plasticity (Sekine et al. 2009). Interestingly, the genes in the increasing 
pattern have different functional implications depending on the location of the editing site in the 
gene. Editing sites in 3’ UTR’s are associated with localization-related GO terms, while CDS-
residing A-to-I editing sites are involved primarily with synapse or glutamate-related GO terms 
(Tables 5.4 and 5.5).  
 
 
5.4. Molecular understanding of the increasing pattern 
Functional implications of the increasing pattern were also interrogated at a molecular 
level. First, the impact of A-to-I editing in CDS on protein function was computationally 
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predicted. Seventy-seven percent (24 out of 31 in CDS) of these sites cause non synonymous 
shifts including one stop codon deletion and six damaging amino acid changes (Table 5.6). 
Second, a potential relationship between editing rates and mRNA abundances was investigated. 
The increasingly-edited sites have some correlation with host mRNA abundances, either positive 
or negative (Figure 5.18a). Interestingly, the distributions of correlation coefficients of editing 
rates with their respect mRNAs are significantly different between CDS-residing editing sites and 
3’UTR-associated editing sites (Figure 5.18b, p-value ≤ 0.05 by Kolmogorov-Smirnov test), 
implying that RNA editing in 3’ UTRs may have relatively richer regulatory potential to affect 
RNA abundances through either RNA stabilization or degradation depending on genes, than ones 
in CDS regions, as generally expected. Finally, the potential of increasingly-edited sites to perturb 
miRNA-binding was explored. After computationally predicting the binding energy between 
miRNA and mRNA regions flanking editing sites (see 5.6 methods), it was found that edited 
mRNA regions generally have lower binding energy with miRNA, compared to mRNA regions 
without RNA editing (Figure 5.19, p-value≤0.001 by two-sample t-test). These results implicate 
possible regulatory roles of RNA editing in the context of brain development.  
 
 
5.5. The increasing pattern in brain disorders 
RNA editing is known to be involved in several human diseases (Slotkin & Nishikura 
2013). I hypothesized that the increasing pattern of A-to-I editing may be especially relevant to 
clinical conditions that involve brain development or damage. First, I looked into two 
neuropathological conditions in which RNA editing has already been implicated, glioblastoma 
and spinal cord injury (SCI). The increasing pattern is selectively and significantly disrupted in 
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both conditions. Specifically, in the previous mouse model of spinal cord injury (Chen et al. 
2013), the editing sites in CDS regions, which show the increasing pattern in mouse brain 
development (Figure 5.6), tend to decrease as the disease progresses from acute and subacute 
phases (Figure 5.20). Also, the editing rates of sites in Group II. Increasing, found in the 
developing brain, are decreased in the glioblastoma samples compared to the flanking non-tumor 
tissues of the same individual, while the editing sites in the Group I. Low and the Group III. High 
keep their editing rates stable regardless of conditions (Fig. 5.21). Given the increase in glia after 
injury and in this tumor, it might be questioned whether this change in cellular composition 
accounts for these disease-associated findings.  However, as shown in the chapter 3 (specifically, 
3.5), simple compositional changes do not seem to be the principle explanation for the 
developmental pattern and its selective alteration in glioblastoma and spinal cord injury. Rather, 
the observation that these pathological states involve reversals of a specific developmental editing 
pattern in brain, i.e. the increasing editing pattern, may provide insights into how the imbalance 
of RNA editing influences these pathological conditions. For example, the aberration of the 
increasing RNA editing might be invovled in the dedifferentiation of cell types in glioblastoma. 
Also, the increasingly-edited sites can have direct clinical significance as a recent study showed 
that two A-to-I editing sites, R/G site in GRIA2 and I/V site in COG3, showing the increasing 
pattern in our dataset affects drug sensitivity of cancer cell lines (Han et al. 2015). 
Second, the enrichment test of genes showing the increasing pattern was performed in 
terms of previously-defined gene sets associated with various neurodevelopmental disorders 
including autism, schizophrenia, bipolar disorder, intellectual disability (ID) as well as disorders 
thought not to be neurodevelopmental, e.g. type 2 diabetes (T2D), Alzheimer disease (AD) and 
Parkinson disease (PD) (Birnbaum et al. 2014; Ripke et al. 2014). Several genes with increasing 
A-to-I editing patterns were involved in neurodevelopmental disorders (Tables 5.7 and 5.8), while 
they are generally not associated with T2D, AD and PD (with one exception, AP3S2 for T2D). 
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This tendency is not limited to the genes with the increasing pattern but in general with genes 
having A-to-I editing sites. While these results do not suggest that editing is a pathogenic factor 
in these disorders, it implies that editing plays a role in the regulation of at least some genes that 
are involved in these conditions. Regarding this, a recent study showed that the balance of RNA 
editing is perturbed by FMRP, a key protein involved in intellectual disability (Bhogal et al. 
2011). Perhaps related to this observation, some genes with the increasing editing pattern are 




Datasets from public database 
RNA-seq raw datasets for various samples were downloaded from the following 
references: Illumina Body Map 2.0 project, GSE69360 (Choy et al. 2015), NIH Roadmap 
Epigenomics (http://www.roadmapepigenomics.org/) and ENCODE project (Bernstein et al. 
2012) for human organ tissues, in-vitro differentiation of human embryonic stem cells (hESCs) 
(van de Leemput et al. 2014) and mouse embryonic stem cells (mESCs) into cortical neurons 
(Hubbard et al. 2013), in-vivo mouse brain tissues (Sauvageau et al. 2013; Fertuzinhos et al. 
2014), primary culture of mouse cortical neurons (Rybak-Wolf et al. 2015), cell type specific 
RNA-seq with mouse cortical tissues (Zhang et al. 2014), single cell RNA-seq with human brain 
tissues (Darmanis et al. 2015), mouse model of spinal cord injury (Chen et al. 2013). The details 
are found in Table 5.9. DNA methylation data used to estimate cellular composition in brain 




RNA-seq data preprocessing 
RNA-seq data from previous studies are aligned by STAR (Dobin et al. 2013). RPKM 
(Reads Per Kilobase per Million) were calculated to estimate gene expression level using HTSeq 
(Anders et al. 2014). 
 
Genome-wide editing rate differences between fetal and adult samples in multiple tissues.  
The computational tool described in Chapter 2 was modified to identify RNA editing 
sites for a simple but thorough comparison of RNA editing rates between fetal and adult samples 
as follows: First, an initial call of RNA editing sites was made, which include the sites with at 
least five sequencing reads with at least two variant-supporting reads. Second, the possible 
genomic variants were removed by excluding SNP sites (except for SNPs of molecular type 
‘cDNA’), sites only shown in a single sample, and sites with multiple variants (by removing those 
sites whose numbers of sequencing reads supporting the major and the minor allele are less than 
95% of total sequencing reads). Finally, A-to-I editing rates were compared between fetal and 
adult samples if the median depth of a site is greater than 20 and a site is in mRNA regions 
(5’UTR, CDS and 3’UTR).  
 
miRNA binding prediction 
Whether a miRNA binds to the mRNA regions around RNA editing sites was 
computationally predicted using the software miRanda (Enright et al. 2003). Specifically, mature 
miRNA sequences are obtained from the well-known database, miRBase (Griffiths-Jones et al. 
2008). For mRNA target sequences, two types of sequences are prepared with flanking regions 
(50 bp upstream and downstream) of editing sites in all mRNA transcripts in refSeq: the reference 
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sequence (‘reference’) and the sequence affected by A-to-I editing (‘edited’). The binding 
energies were calculated between a miRNA and both a ‘reference’ and ‘edited’ mRNA. The 
comparison was performed with all the predicted binding pairs of miRNAs and mRNA targets. 
 
Bioinformatics for functional analyses 
The coordinates in the human genome (UCSC hg19) was converted to the mouse genome 
(UCSC mm10) using UCSC coordinate converter or liftOver (https://genome.ucsc.edu/cgi-
bin/hgLiftOver). The effect of CDS-associated RNA editing on protein functions was predicted 
by PolyPhen-2 (Maathuis et al. 2000). Enrichment of genes in pre-defined gene sets was 




Figure 5.1 Fetal and adult editing rates at sites in ‘Group II. increasing’. The editing rates at the sites in the groups in Figure 4.2 were 
compared between fetal and adult tissues for brain (a), heart (b) and liver (c). Only sites with sequencing depth greater than 20 in both fetal and 
adult tissues were used. Note that these brain samples are independent from the 33 discovery samples in Figure 3.4. The same colors from Figure 
4.2 are used to indicate the three developmental pattern groups: ‘Group I. Low’ (blue), ‘Group II. Increasing’ (green), ‘Group III. High’ (red). 
Color shade in a,b,c and point size in e are proportional to three categories of sequencing depth: low (less than 20), medium (20 to 50), high 




Figure 5.2 Differences of mean editing rates between fetal and adult samples across multiple 
tissues. At least three samples, except for a liver fetal tissue, are used to calculate mean editing 
rates for fetal and adult samples respectively. Note that 3 fetal and 3 adult samples were selected 
from our 33 discovery brain tissues. ANOVA reveals that brain, liver and lung show clear 
separation among patterns (p-value ≤ 0.01), though the increasing pattern is much more marked 








Figure 5.3 mRNA expression levels of ADAR enzymes. In each tissue, fetal and adult samples 
are compared: (a) ADAR1 (b) ADAR2. Note that boxplots are generated for visualization, even 
with 3 fetal and 3 adult samples in every tissue, except for adult heart (4 samples) and fetal liver 






Figure 5.4 Genome-wide editing rate differences between fetal and adult samples in 
multiple tissues. (a) Histogram of mean editing rate difference between fetal and adult samples. 
Mean editing rate difference is defined by the mean editing rate of adult samples minus the mean 
editing rate of fetal samples. The blue is used to describe a site whose mean editing rate is greater 








Figure 5.5 Venn diagram showing the overlap of sites across brain, liver and lung. Sites 











Figure 5.6 Increasing pattern in mouse brain development. The increasing pattern is 
conserved in mouse brain development (E: embryonic day, P: postnatal day in x-axis). Each line 
represents a conserved A-to-I editing site showing the increasing pattern in human brain 
development. The same colors as in Figure 3.6 are used to show conserved relative editing rates 








Figure 5.7 Increasing pattern in mouse brain development according to gene regions. The conserved A-to-I editing sites are classified 
according to clusters of increasing pattern (Figure 3.6) and gene regions. Most of the A-to-I editing sites in CDS regions show an increasing 
pattern (except for the site in NEIL1 in the cluster 5, denoted with a brown line). Dot size is proportional to three categories of sequencing depth: 




Figure 5.8 mRNA expression levels of ADAR1 (blue) and ADAR2 (purple) in mouse brain 
development. Lines are generated by locally weighted scatterplot smoothing (LOESS) regression 












Figure 5.9 A-to-I editing sites in NEIL1 in human brain development. NEIL1 in the human 
genome has Alu repeats forming double-stranded structures near A-to-I editing sites. A double-
stranded structure is depicted by arcs, which connect two base-paired nucleotides (‘baseparing 
arcs’) using an R library, R-CHIE (www.e-rna.org/r-chie). A-to-I editing sites with two different 








Figure 5.10 A-to-I editing sites in PDZD7 in human brain development. The A-to-I editing 
site in the PDZD7 is only found in a transcript specific to the human genome. This A-to-I editing 







Figure 5.11 The magnitude of editing rate changes found at increasingly-edited sites. The 
magnitude of editing rate changes is defined as the mean editing rate difference between fetal and 
post-infant samples for human brain development while it is defined as the mean editing rate 
differences between samples of in-vitro day 0 and 7 and samples of in-vitro day 33 and 49 for 
hESC samples. The comparisons between samples in human brain development and samples in 
in-vitro differentiation of hESC into cortical neurons are performed separately according to the 
five increasing clusters defined in figures 3.4 and 3.6. The x-axis numbers indicate the clusters, 






Figure 5.12 The increasing editing pattern in the differentiation of human embryonic stem 
cells into cortical neurons. Numbers are matched with Figures 3.4 and 3.6. The letters in the 
upper bar stands for the following (van de Leemput et al. 2014): P, pluripotency; ND, neural 
differentiation; CS, cortical specification; DL, deep layer; UL, upper layer. Note that colors 








Figure 5.13 Editing rate changes in in-vitro differentiation of mESCs to cortical neurons. 
Different colors indicate different clusters in Figures 3.4 and 3.6 to show conserved relative 
editing rates within the increasing pattern. Days In-vitro (DIV) descriptions were adapted from 
(Hubbard et al. 2013). Dot size is proportional to three categories of sequencing depth: low (less 











Figure 5.14 Cellular markers in in-vitro differentiation of hESCs to cortical neurons. Expression levels of markers are measured by RNA-seq 
with an RPKM unit: OCT4 and  Nanog for pluripotency, PAX6 and Sox1 for neural differentiation, EMX2 and OTX2 for cortical specification, 
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TBR1 and BCL11B (CTIP2) for deep layer neurons, CACNE1 for upper layer neurons, GFAP for glial cells, MAP2 for dendrites, MAPT for 




Figure 5.15 Editing rate change during the culture of primary mouse neuron. Only the 
conserved sites whose sequencing depth is sufficient to estimate editing rate reliably are depicted. 
Note that colors indicate the corresponding clusters in Figure 3.6. Point sizes are proportional to 









Figure 5.16 Cellular markers in primary culture of mouse cortical neurons. Expression 
levels of markers are measured by RNA-seq with an RPKM unit: Rbfox3 (NeuN) for neurons, 








Figure 5.17 The enriched GO terms for genes with the increasing pattern. Two GO 










Figure 5.18 Correlation of editing rates with mRNA expression levels. Spearman correlation 
coefficient between editing rates and mRNA expression levels are calculated at the sites showing 
the increasing pattern. When there are multiple editing sites in a gene, the highest correlation 
value is assigned to a gene. (a) Distribution of correlation coefficient at the total sites with the 
increasing pattern (b) Distributions of correlation coefficients are separately described according 








Figure 5.19 Binding energy between miRNA and mRNA target. Binding of miRNA to an 
mRNA region spanning increasingly-edited sites are computationally predicted and the associated 
binding energy is compared between canonical mRNA sequence (‘Reference’) and mRNA 






Figure 5.20 Editing rate changes in the mouse model of spinal cord injury at the CDS-
residing conserved editing sites in the increasing pattern. Sites with enough sequencing depth 
are only described. Colors indicate the corresponding clusters in Figure 3.6. Point sizes are 
proportional to three categories of sequencing depth: low (less than 20), medium (20 to 50), high 








Figure 5.21 The comparison of editing rates in the groups of selected sites between a 
glioblastoma and neighboring non-tumor tissue. Each figure is generated with an independent 
patient. Color denote group same as Figure 4.2. Color shade is proportional to three categories of 












Chromosome Coordinate Gene Gene reion 
Mouse genome 
Location Reference 
chr1 2436080 PLCH2 CDS chr4:154984234 G 
chr1 40147856 HPCAL4 3' UTR chr4:123191224 A 
chr1 41089410 RIMS3 3' UTR chr4:120893807 A 
chr1 160185788 DCAF8 3' UTR chr1:172196141 G 
chr1 160302244 COPA CDS chr1:172092348 A 
chr1 160319987 NCSTN CDS chr1:172074326 T 
chr2 25381529 EFR3B 3' UTR chr12:3962972 C 
chr2 73171432 SFXN5 3' UTR chr6:85215002 G 
chr2 172605884 DYNC1I2 3' UTR chr2:71264165 A 
chr2 202486541 TMEM237 3' UTR chr18:48047793 A 
chr3 42590546 SEC22C 3' UTR chr9:121681599 A 
chr3 119545199 GSK3B 3' UTR chr16:38241020 A 
chr3 179093028 MFN1 CDS chr3:32561485 A 
chr4 77979680 CCNI CDS chr5:93189584 T 
chr4 158257879 GRIA2 CDS chr3:80706908 T 
chr4 158281294 GRIA2 CDS chr3:80692286 T 
chr5 156904831 ADAM19 3' UTR chr11:46146839 A 
chr5 156904833 ADAM19 3' UTR chr11:46146837 A 
chr5 156904853 ADAM19 3' UTR chr11:46146821 A 
chr5 156904922 ADAM19 3' UTR chr11:46146777 A 
chr5 156904929 ADAM19 3' UTR chr11:46146770 T 
chr5 156904947 ADAM19 3' UTR chr11:46146752 A 
chr5 156904950 ADAM19 3' UTR chr11:46146749 A 
chr5 156904965 ADAM19 3' UTR chr11:46146734 A 
chr5 156905396 ADAM19 3' UTR chr11:46146102 A 
chr5 156905397 ADAM19 3' UTR chr11:46146101 A 
chr5 156905398 ADAM19 3' UTR chr11:46146100 A 
chr5 156905411 ADAM19 3' UTR chr11:46146089 A 
chr5 156905556 ADAM19 3' UTR chr11:46145955 T 
chr5 156905560 ADAM19 3' UTR chr11:46145951 G 
chr6 44120349 TMEM63B CDS chr17:45662949 T 
chr6 102337702 GRIK2 CDS chr10:49272776 T 
chr6 102372572 GRIK2 CDS chr10:49244347 T 
chr6 102372589 GRIK2 CDS chr10:49244330 T 
chr7 25160004 CYCS 3' UTR chr6:50562746 T 
chr8 9639522 TNKS 3' UTR chr8:34826795 T 
chr8 12886333 KIAA1456 3' UTR chr8:36518849 A 
chr9 127712691 SCAI 3' UTR chr2:39073337 T 
chr9 136229572 SURF4 3' UTR chr2:26921169 T 
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chr9 139335555 SEC16A 3' UTR chr2:26410275 T 
chr9 139335597 SEC16A 3' UTR chr2:26410306 C 
chr9 139335623 SEC16A 3' UTR chr2:26410329 C 
chr9 139335882 SEC16A 3' UTR chr2:26410574 C 
chr10 102121601 SCD 3' UTR chr19:44304213 G 
chr11 68523904 CPT1A 3' UTR chr19:3384947 T 
chr11 68524809 CPT1A 3' UTR chr19:3384135 G 
chr11 75316685 MAP6 3' UTR chr7:99317823 G 
chr11 75316752 MAP6 3' UTR chr7:99317759 A 
chr11 75316759 MAP6 3' UTR chr7:99317752 A 
chr11 82868441 PCF11 5' UTR chr7:92669661 T 
chr11 105804694 GRIA4 CDS chr9:4456006 T 
chr11 119532688 PVRL1 3' UTR chr9:43806689 A 
chr12 5021742 KCNA1 CDS chr6:126642158 T 
chr12 48736610 ZNF641 3' UTR chr15:98288379 T 
chr12 56633548 ANKRD52 3' UTR chr10:128394072 A 
chr12 120531332 CCDC64 3' UTR chr5:115649059 A 
chr12 132407137 ULK1 3' UTR chr5:110785005 T 
chr14 20920211 OSGEP CDS chr14:50919694 T 
chr14 26917530 NOVA1 CDS chr12:46700334 T 
chr15 40710778 IVD 3' UTR chr2:118880849 G 
chr15 65425334 PDCD7 CDS chr9:65346924 G 
chr15 75646087 NEIL1 CDS chr9:57144307 T 
chr15 89739330 ABHD2 3' UTR chr7:79360823 A 
chr17 3763779 CAMKK1 3' UTR chr11:73041884 G 
chr17 29862338 RAB11FIP4 3' UTR chr11:79695576 C 
chr17 37826529 PNMT CDS chr11:98387978 G 
chr17 42154831 HDAC5 3' UTR chr11:102195028 T 
chr17 42154907 HDAC5 3' UTR chr11:102195105 C 
chr17 42475813 GPATCH8 CDS chr11:102479070 T 
chr17 56049824 VEZF1 3' UTR chr11:88083835 A 
chr17 56049829 VEZF1 3' UTR chr11:88083830 G 
chr17 79780692 FAM195B 3' UTR chr11:120543288 A 
chr18 51061986 DCC 3' UTR chr18:71253914 T 
chr18 51061990 DCC 3' UTR chr18:71253910 C 
chr19 14593605 GIPC1 CDS chr8:83661176 A 
chr19 14593693 GIPC1 CDS chr8:83661088 T 
chr19 18892789 CRTC1 3' UTR chr8:70382669 T 
chr19 38887763 SPRED3 3' UTR chr7:29160661 T 
chr19 38888055 SPRED3 3' UTR chr7:29160385 C 
chr19 38888069 SPRED3 3' UTR chr7:29160371 T 
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chr19 38888095 SPRED3 3' UTR chr7:29160345 T 
chr19 38889352 SPRED3 3' UTR chr7:29159681 T 
chr19 54485579 CACNG8 CDS chr7:3415084 A 
chr20 2128469 STK35 3' UTR chr2:129831568 G 
chr20 5175539 CDS2 3' UTR chr2:132309649 A 
chr20 5175805 CDS2 3' UTR chr2:132309873 A 
chr20 44802643 CDH22 3' UTR chr2:165111769 A 
chr20 44802728 CDH22 3' UTR chr2:165111853 T 
chr21 30953750 GRIK1 CDS chr16:87940543 T 
chr22 37765609 ELFN2 3' UTR chr15:78668715 G 
chrX 54955567 TRO CDS chrX:150648527 T 
chrX 84346885 APOOL 3' UTR chrX:112384042 A 
chrX 84346892 APOOL 3' UTR chrX:112384049 A 
chrX 122598962 GRIA3 CDS chrX:41654252 A 
chrX 151358319 GABRA3 CDS chrX:72445292 T 
 
Table 5.1 The conserved sites between human and mouse among the sites with the 
increasing pattern. Among 742 A-to-I editing sites showing the increasing pattern in human 










Table 5.2 Increasing pattern in mouse brain development. See appendix 2. Site: 
corresponding location of A-to-I editing sites found in human brain tissues in UCSC mouse 
genome mm10; Increasing cluster (Clu.):  an index of cluster described in figures 3.4 and 3.6; 
Gene and gene region (Reg.): gene annotation of A-to-I editing sites based on RefSeq; Editing 
rate (ER) and Depth: editing rate with sequencing depth at a given site are shown according to 























25 11.31 2.02E-05 0.033 
COPA, GRIK2, SNX1, VPS53, GIPC1, 
TIMM50, ZFYVE20, HOOK3, SEC16A, 
SEC22C, PEX13, TNKS, RAB2B, 
VPS41, AP4S1, RAB11FIP4, PHAX, 
GRIA2, RAB36, GSK3B, PEX26, 






27 12.22 2.36E-05 0.038 
COPA, GRIK2, SNX1, VPS53, GIPC1, 
TIMM50, ZFYVE20, HOOK3, SEC16A, 
SEC22C, PEX13, TNKS, COX18, 
RAB2B, VPS41, AP4S1, RAB11FIP4, 
PHAX, GRIA2, ULK1, RAB36, GSK3B, 
PEX26, GGA2, NUP43, SRP9, SSR3 
GOTERM_
BP_FAT 
GO:0050806 protein transport 24 10.86 5.13E-05 0.083 
RAB2B, COPA, GRIK2, VPS53, SNX1, 
GIPC1, VPS41, TIMM50, ZFYVE20, 
AP4S1, HOOK3, RAB11FIP4, PHAX, 
RAB36, GSK3B, SEC16A, PEX26, 
SEC22C, PEX13, TNKS, GGA2, 





















COPA, GRIK2, SNX1, GIPC1, VPS41, 
AP4S1, GSK3B, PEX26, PEX13, TNKS, 











COPA, GRIK2, SNX1, GIPC1, VPS41, 
AP4S1, GSK3B, PEX26, PEX13, TNKS, 










COPA, GRIK2, SNX1, GIPC1, VPS41, 
ZFYVE20, AP4S1, TAPBP, HOOK3, 
PHAX, GSK3B, PEX26, PEX13, 





















RAB2B, COPA, CRCP, SNX1, VPS41, 
ZFYVE20, AP4S1, TAPBP, HOOK3, 
RIMS3, GRIA2, ULK1, SEC16A, 










COPA, GRIK2, GSK3B, PEX26, SNX1, 





































36 16.29 7.75E-08 0.000 
MAVS, ACOX1, COPA, APOOL, 
MTDH, TIMM50, GIPC1, SFXN5, 
HOOK3, TAPBP, CDS2, ATP5S, 
PEX13, TNKS, COX18, GOLGA3, 
ACSL6, RAB2B, CACNG8, SCD, 
GRIA3, VPS41, GRIA4, SYNJ2BP, 
NDUFA10, CPT1A, NCSTN, MFN1, 
GRIA2, ULK1, L2HGDH, PEX26, 
MDM2, TMPO, SRP9, SSR3 
GOTERM_
CC_FAT 
GO:0031967 organelle envelope 20 9.05 1.81E-04 0.239 
MAVS, APOOL, MTDH, SCD, CYCS, 
TIMM50, SYNJ2BP, NDUFA10, 
CPT1A, SFXN5, CBX5, CDS2, MFN1, 
L2HGDH, ATP5S, TNKS, TMPO, 
COX18, NUP43, ACSL6 
GOTERM_ GO:0031975 envelope 20 9.05 1.88E-04 0.249 MAVS, APOOL, MTDH, SCD, CYCS, 
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CC_FAT TIMM50, SYNJ2BP, NDUFA10, 
CPT1A, SFXN5, CBX5, CDS2, MFN1, 
L2HGDH, ATP5S, TNKS, TMPO, 






5 2.26 6.47E-04 0.855 




GO:0030139 endocytic vesicle 6 2.71 7.26E-04 0.959 








COPA, XIAP, PNMT, GNE, RPL13, 
GIPC1, GSR, PGPEP1, SORBS1, 
PSMB2, EEF2K, GUCY1A3, RPS20, 
INPP5B, SMAD9, VHL, CYCS, EIF2S3, 
VPS41, RIC8B, TPMT, PHAX, 
PKNOX1, ULK1, PPIA, GSK3B, MTR, 










MAVS, APOOL, CYCS, TIMM50, 
SYNJ2BP, NDUFA10, CPT1A, SFXN5, 








MAVS, APOOL, PDP2, CYCS, 
TIMM50, SYNJ2BP, NDUFA10, 
CPT1A, SFXN5, CDS2, MFN1, 








COPA, GRIA2, CACNG8, ULK1, 










RAB2B, COPA, MTDH, CACNG8, 
SCD, GIPC1, GRIA3, GRIA4, AP4S1, 
CBX5, TAPBP, GRIA2, ULK1, MDM2, 











MAVS, APOOL, TIMM50, SYNJ2BP, 
NDUFA10, CPT1A, SFXN5, CDS2, 
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MAVS, ACOX1, APOOL, PDP2, 
CXORF23, VHL, CYCS, AASS, 
TIMM50, SYNJ2BP, NDUFA10, 
MRPL30, CPT1A, SFXN5, CDS2, GSR, 
MFN1, L2HGDH, IVD, PPM1K, 




























COPA, GRIA2, CACNG8, ULK1, 










14.886 GRIK1, GRIK2, GRIA4 
GOTERM_
CC_FAT 
GO:0043198 dendritic shaft 3 1.36 
0.0120833
89 










16.279 GNPNAT1, SURF4, UGGT1, GOLGA3 
GOTERM_
CC_FAT 
GO:0044439 peroxisomal part 4 1.81 
0.0151434
66 
18.316 ACOX1, PEX26, PEX13, ACSL6 
GOTERM_
CC_FAT 
GO:0044438 microbody part 4 1.81 
0.0151434
66 











TGOLN2, COPA, CACNG8, GIPC1, 
VPS41, GRIA3, GRIA4, NCSTN, 





Table 5.3 Gene ontology (GO) terms associated with genes with increasing editing pattern. Category: GO category, GOTERM_BP_FAT for 
biological process and GOTERM_CC_FAT for cellular component; ID: GO ID; Term: GO term; Count: the number of genes associated with a 
given term; Percentage: The proportion of genes with increasing pattern in a given term; p-value and FDR (False Discovery Rate): based on 




























RAB2B, AP3S2, VPS53, SNX1, VPS41, TIMM50, 
ZFYVE20, AP4S1, HOOK3, RAB11FIP4, PHAX, 
RAB36, ULK1, GSK3B, SEC16A, PEX26, SEC22C, 











RAB2B, AP3S2, VPS53, SNX1, VPS41, TIMM50, 
ZFYVE20, AP4S1, HOOK3, RAB11FIP4, PHAX, 
RAB36, GSK3B, SEC16A, PEX26, SEC22C, PEX13, 












RAB2B, AP3S2, VPS53, SNX1, VPS41, TIMM50, 
ZFYVE20, AP4S1, HOOK3, RAB11FIP4, PHAX, 
RAB36, GSK3B, SEC16A, PEX26, SEC22C, PEX13, 












RAB2B, AP3S2, CRCP, SNX1, VPS41, ZFYVE20, 
AP4S1, TAPBP, HOOK3, RIMS3, ULK1, SEC16A, 












AP3S2, SNX1, VPS41, ZFYVE20, AP4S1, TAPBP, 
HOOK3, PHAX, GSK3B, PEX26, PEX13, SEC22C, 













GSK3B, PEX26, AP3S2, SNX1, VPS41, TNKS, PEX13, 














GSK3B, PEX26, AP3S2, SNX1, VPS41, TNKS, PEX13, 











MAVS, APOOL, ACOX1, MTDH, TIMM50, SFXN5, 
HOOK3, TAPBP, CDS2, ATP5S, PEX13, TNKS, 
COX18, GOLGA3, ACSL6, RAB2B, CACNG8, SCD, 
VPS41, SYNJ2BP, NDUFA10, CPT1A, ULK1, 
L2HGDH, PEX26, MDM2, TMPO, SSR3 
GOTERM_CC_F GO:00319 organelle 19 9.60 9.93E- 0.128 MAVS, APOOL, MTDH, SCD, CYCS, TIMM50, 
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AT 67 envelope 05 SYNJ2BP, NDUFA10, CPT1A, SFXN5, CBX5, CDS2, 










MAVS, APOOL, MTDH, SCD, CYCS, TIMM50, 
SYNJ2BP, NDUFA10, CPT1A, SFXN5, CBX5, CDS2, 












MAVS, APOOL, PDP2, CYCS, TIMM50, SYNJ2BP, 
NDUFA10, CPT1A, SFXN5, CDS2, L2HGDH, IVD, 











MAVS, CDS2, APOOL, L2HGDH, ATP5S, CYCS, 












MAVS, ACOX1, APOOL, PDP2, CXORF23, VHL, 
CYCS, AASS, TIMM50, SYNJ2BP, NDUFA10, 
MRPL30, CPT1A, SFXN5, CDS2, GSR, L2HGDH, IVD, 











MAVS, CDS2, APOOL, L2HGDH, ATP5S, TIMM50, 









XIAP, GNE, RPL13, GSR, PGPEP1, PSMB2, EEF2K, 
GUCY1A3, RPS20, INPP5B, SMAD9, VHL, CYCS, 
EIF2S3, VPS41, RIC8B, TPMT, PHAX, PKNOX1, 








































































TGOLN2, RAB2B, MGAT4A, GNPNAT1, AP3S2, 
VPS53, SNX1, VPS41, AP4S1, TAPBP, HOOK3, NMT2, 













CDS2, APOOL, L2HGDH, ATP5S, TIMM50, 
NDUFA10, COX18, SFXN5, CPT1A 
 














8 2.27 3.01E-07 0.000 
GRIA2, GRIK1, GRIK2, GABRA3, 
KCNA1, GIPC1, GRIA4, NOVA1 
GOTERM_BP_FAT GO:0019226 
transmission of 
nerve impulse  
8 2.27 8.92E-07 0.001 
GRIA2, GRIK1, GRIK2, GABRA3, 






















nerve impulse  




8 2.27 3.10E-05 0.043 
GRIA2, GRIK1, GRIK2, GABRA3, 





system process  





5 1.42 6.21E-05 0.085 





nerve impulse  
5 1.42 8.41E-05 0.115 
GRIA2, GRIK1, GRIK2, GIPC1, 
GRIA4 




system process  
GRIA4 
GOTERM_CC_FAT GO:0044456 synapse part  7 1.98 1.48E-06 0.002 
GRIA2, GRIK1, GRIK2, GABRA3, 




6 1.70 1.67E-06 0.002 





5 1.42 1.88E-06 0.002 





6 1.70 2.89E-06 0.003 
COPA, GRIA2, CACNG8, GIPC1, 
GRIA3, GRIA4 
GOTERM_CC_FAT GO:0045202 synapse  7 1.98 1.23E-05 0.015 
GRIA2, GRIK1, GRIK2, GABRA3, 









5 1.42 2.79E-05 0.033 






5 1.42 5.67E-05 0.067 
COPA, GRIA2, CACNG8, GRIA3, 
GRIA4 
GOTERM_CC_FAT GO:0030054 cell junction  7 1.98 1.03E-04 0.121 
GRIA2, SORBS1, GRIK1, GRIK2, 
GABRA3, GRIA3, GRIA4 
GOTERM_CC_FAT GO:0030425 dendrite  5 1.42 1.05E-04 0.125 





9 2.55 1.41E-04 0.166 
NCSTN, MFN1, COPA, GRIA2, 




membrane part  
12 3.40 1.42E-04 0.168 
NCSTN, COPA, GRIA2, SORBS1, 
GRIK1, CACNG8, GRIK2, GABRA3, 




bounded vesicle  
7 1.98 1.43E-04 0.169 
NCSTN, COPA, GRIA2, CACNG8, 
GIPC1, GRIA3, GRIA4 
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chr1 2436080 PLCH2 nonsynonymous R->G Neutral 
chr1 160302244 COPA nonsynonymous I->V Neutral 
chr1 160319987 NCSTN nonsynonymous S->G Neutral 
chr1 225974581 SRP9 synonymous L->L NA 
chr3 179093028 MFN1 synonymous A->A NA 
chr4 77979680 CCNI nonsynonymous R->G Deleterious 
chr4 158257879 GRIA2 synonymous Q->Q NA 
chr4 158281294 GRIA2 nonsynonymous R->G Neutral 
chr6 44120349 TMEM63B nonsynonymous Q->R Deleterious 
chr6 102337702 GRIK2 nonsynonymous Y->C Neutral 
chr6 102372572 GRIK2 synonymous G->G NA 
chr6 102372589 GRIK2 nonsynonymous Q->R Neutral 
chr10 102777342 PDZD7 stoploss X->W NA 
chr11 105804694 GRIA4 nonsynonymous R->G Neutral 
chr12 5021742 KCNA1 nonsynonymous I->V Deleterious 
chr14 20920211 OSGEP nonsynonymous I->M Deleterious 
chr14 26917530 NOVA1 nonsynonymous S->G Neutral 
chr15 65425334 PDCD7 synonymous A->A NA 
chr15 75646087 NEIL1 synonymous K->K NA 
chr17 37826529 PNMT nonsynonymous S->G Neutral 
chr17 42475813 GPATCH8 nonsynonymous K->R Deleterious 
chr19 14593605 GIPC1 nonsynonymous T->A Neutral 
chr19 14593693 GIPC1 synonymous P->P NA 
chr19 54485579 CACNG8 nonsynonymous S->G Neutral 
chr21 30953750 GRIK1 nonsynonymous Q->R Neutral 
chrX 54955567 TRO nonsynonymous S->G Deleterious 
chrX 122598962 GRIA3 nonsynonymous R->G Neutral 
chrX 151358319 GABRA3 nonsynonymous I->M Neutral 
 
Table 5.6 Effect of A-to-I editing sites in CDS region. Chromosome and  Coordinate: location 
of A-to-I editing sites in UCSC human genome hg19; Gene: gene annotation based on RefSeq; 
Effect: synonymous or nonsynonymous; Description and Nonsynonymous prediction: amino acid 






















SCZ 722 4 0.336 4 0.088 
SLC4A8, CBX5, 
GFOD2, PLCH2 
BPAD 123 3 0.127 3 0.214 
MGAT4A, MRPL30, 
PTPRT 
ID 88 3 0.059 3 0.119 
AP4S1, GRIA3, 
GRIK2 
T2D 66 1 NA 1 NA AP3S2 
AD 42 0 NA 0 NA 
 
PD 41 0 NA 0 NA 
 
 
Table 5.7 Disease association of genes with increasing editing pattern. Enrichment of genes 
with the increasing pattern in previously-defined gene sets associated with various 
neurodevelopmental disorders including autism (ASD), schizophrenia (SCZ), biplolar (BPAD), 
intellectual disability (ID) and disorders thought not to be neurodevelopmental: type 2 diabetes 
(T2D), Alzheimer disease (AD) and Parkinson disease (PD). Brain-expressed genes indicate 
genes whose RPKM are greater than 1 at least one samples in the 33 samples. p-value is obtained 








Disease-associated genes RNA editing site 
showing increasing 










Functional  chr1 237066314 
CCDC64 
coiled‐coil domain 


























kinase 3 beta  
ASD 
DATABASE  
Functional  chr3 119545199 
GRIK2 
glutamate receptor, 






































chromobox homolog 5 
(HP1 alpha homolog, 
Drosophila)  







Domain Containing 2 












nsferase, isozyme A  
BPAD GWAS  GWAS  chr2 99239382 
MRPL30 
mitochondrial 
ribosomal protein L30  













type, T  
BPAD GWAS  GWAS  chr20 40705281 
AP4S1 
adaptor‐related protein 
complex 4, sigma 1 
subunit  









ionotrophic, AMPA 3  
ID   NA chrX 122598962 
AP3S2 
adaptor-Related 









Table 5.8 Genes involved in neurodevelopmental disorders with increasing A-to-I editing 
patterns. Detail description of genes associated with diseases. Disease and Genetic evidence is 
obtained from (Birnbaum et al. 2014). 
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Section Description Reference Accession 
5.1 Tissue 
variation 




Kidney: adult (60 year old) ERR030885, ERR030893 
Lung: adult (65 year old) ERR030879, ERR030896 
Skeletal muscle: adult (77 year 
old) 
ERR030876, ERR030899 
Brain (PFC): fetal (22 week) 
ENCODE 
ENCLB181ZZZ 
Heart: adult (34 year) ENCLB172ZZZ 
Heart: fetal (28 weak) ENCLB183ZZZ 
Kidney (metanephros): fetal 
(24 week) 
ENCLB186ZZZ 
Liver: adult (32 year) ENCLB174ZZZ 
Liver: fetal (20 week) ENCLB187ZZZ 
Lung: fetal (20 week) ENCLB189ZZZ 






In-vivo mouse E13.5 (pooled) 
GSE49581 
GSM1202240, GSM1202241 
In-vivo mouse E15.5 (pooled) GSM1202244, GSM1202245 
In-vivo mouse E18.5 (pooled) GSM1202232, GSM1202233 
In-vivo mouse P7 (pooled) GSM1202249, GSM 1202250 




























In-vitro differentiation of 
hESC to cortical neuron 
GSE56796 All 
In-vitro differentiation of 








Mouse primary cortical neuron 
culture day7 
SRR1993668 




Mouse primary cortical neuron 
culture day21 
SRR1993670 




Mouse model of acute spinal 
cord injury, CTRL (pooled) 
GSE45376 
SRR789190,SRR789191 
Mouse model of acute spinal 
cord injury, 2day (pooled) 
SRR789193,SRR789194,SR
R789195 
Mouse model of acute spinal 




Table 5.9 Previous RNA-seq datasets. Section: section in the chapter 5; Description: summary 


















This study reveals systematic and dynamic aspects of RNA editing in human brain across 
development and in two disease states. Further studies of the molecular mechanisms underlying 
dynamic RNA editing will give new insights into the regulation of sequence diversity in the 













The recent expansion of RNA sequencing datasets has led to the identification of a huge 
number of RNA editing sites (Ramaswami & Li 2014). Among the emergent questions that have 
arisen from this identification are which of these sites are functional and how are they regulated. 
Constructing a spatiotemporal atlas of RNA editing is instrumental to answering such questions 
(Li & Church 2013). This study explored the genome-wide landscape of RNA editing in human 
brain development to advance understanding of the function and regulation of A-to-I editing. The 
genome-wide approach discovered that there are different levels of RNA editing rates both at a 
given site across development and at a given state of cell differentiation across multiple genes, 
which shows the ‘dynamic’ nature of RNA editing.  
The dynamic aspects of A-to-I editing were summarized by three distinct editing patterns: 
stable high, stable low and increasing across cortical development. Identification of these patterns 
helps us to appreciate how A-to-I editing is regulated and functionally-implicated in the 
development of the nervous system. Specifically, the temporal expression of ADAR enzymes and 
the secondary structures of RNA species, as potential trans- and cis- regulatory mechanisms 
respectively, likely account at least in part for the developmental A-to-I editing patterns. 
Interestingly, the increasing A-to-I editing pattern across brain development is associated 
temporally with the growth of cortical layers and neuronal maturation. 
However, the biochemical meaning of the proposed mechanisms for dynamic A-to-I 
editing patterns remains to be explored. Specifically, although the suggested cis- regulatory 
mechanism - RNA secondary structure – is computationally quantified in this study, a molecular 
exploration has yet to be completed. Also, the mechanism behind stable high-editing pattern 
throughout brain development is still unclear as many sites with low degrees of double-stranded 
structure have high editing rates during fetal life despite relatively-low expression of ADAR 
enzymes. There might be cofactors to enhance A-to-I editing (Garncarz et al. 2013) or unknown 
facilitatory mechanisms associated with high-edited sites. For example, the distance between 
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editing sites and the hairpin structure may affect editing rates synergistically with the degree of 
double-stranded structure. 
In addition, although this study showed the correlation of A-to-I editing changes with 
neuronal maturation in neurogenesis or pathological conditions in brain disorders, mechanistic 
understanding on how the A-to-I editing change mediates those cellular phenotypes is still very 
limited. Some possiblilities were investigated including amino acid changes in functional 
domains or perturbation of miRNA-binding potential,  but further studies of molecular 
mechanisms are necessary to fully appreciate their functional importance. 
Finally, it should be noted that an emphasis on human samples in this study identifies 
many developmentally-regulated editing sites in primate-specific regions of the genome, 
especially in Alu repeats. So far, many functional studies on RNA editing have focused on 
evolutionarily-conserved sites, which are relatively few (Pinto et al. 2014). However, considering 
that the number of RNA editing sites has expanded in primates, especially in brain tissues, it is 
important to identify which sites are functionally relevant. The increasing editing pattern might 
provide a clue to this question. For example, RNA editing sites showing developmentally-
increasing editing patterns only in human-specific transcripts, such as one in found in PDZD7 
(see section 5.2) can be candidates for molecular experiments. In addition, a comparison of Alu-
containing transcripts with and without the increasing A-to-I editing pattern will promote the 
understanding of the A-to-I editing in Alu-containing transcripts, and more generally, the role of 
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